Reports

Research Reports

Continuous Renal Replacement Therapy (CRRT) Market
June, 2022

The global continuous renal replacement therapy market was valued at USD 1.4 billion in 2021 and it is anticipated to grow at a CAGR 6.3% during the forecast period to reach up to USD 2.6 billion by 2031.

Continuous renal replacement therapy (CRRT) is a popular choice of therapy usually used for renal support in critically ill patients with acute kidney injury (AKI), primarily in hemodynamically unstable patients. It comprises the solute removal from the blood through the process of hemodialysis or hemofiltration or a combination of both methods. The CRRT therapy is generally carried out for about 24 hours in an ICU, making it altered from other kinds of conventional renal replacement therapies such as intermittent hemodialysis (IHD) which lasts for about 4 to 6 hours or even less.

Global Continuous Renal Replacement Therapy Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$1.4 bn
Market Size in 2031$2.6 bn
Growth Rate (2021-31)6.3%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Modality, Age Group, and Region
Key CompaniesBaxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The increase in the prevalence of incidence of acute kidney injury is propelling the growth of the market during the forecast period. The increasing global incidence of AKI/AKF is, therefore, expected to increase the demand for CRRT. According to the International Society of Nephrology (INR), an anticipated 13.3 million cases of AKI are registered annually across the globe. This is anticipated to boost the adoption of continuous renal replacement therapy at a rapid rate. With the rapid growth in the geriatric population globally, the prevalence of kidney-related diseases is expected to increase significantly. This, in turn, is anticipated to propel the growth of the CRRT market at a significant rate during the forecast period.

Similarly, emerging markets in APAC and RoW are also offering various growth opportunities during the forecast period. Emerging markets like China, India, Brazil, and Mexico are anticipated to offer significant growth opportunities for players in the CRRT market. According to an article published by the Journal of Clinical and Diagnostic Research (JCDR) 2018, in a prospective observational study conducted on 100 critically ill patients. In India, AKI was observed in 17.3 cases/1,000 persons. To leverage the significant growth opportunities in emerging countries, players are progressively focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers. Additionally, regulatory policies in the Asia Pacific region are more adaptive and business-friendly owing to the less-stringent data requirements. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further encourage CRRT product manufacturers to focus on the emerging markets.

Market Restraints and Challenges

The key factor hindering the market growth is the high procedural cost of CRPT. As the population in emerging nations is price-sensitive, they prefer lower-priced products. While the cost of CRRT in developing countries is high which makes these procedures are still unaffordable for a large portion of the population owing to the low purchasing power. This restrains the demand and uptake of CRRT in developing as well as developed countries.

Global Continuous Renal Replacement Therapy Market segmentation

The report analyses the global continuous renal replacement therapy market based on product, modality, age group, and region.

Global Continuous Renal Replacement Therapy Market by Product

Based on product, it is segmented into dialysates and replacement fluids, disposables, Hemofilters, bloodline sets & tubes, and others. The dialysates and replacement fluid segment is likely to dominate the market during the forecast period. The key factors such as benefits of convection and diffusion for the removal of solutes, which is another major factor boosting the market growth during the forecast period.

Global Continuous Renal Replacement Therapy Market by Modality

Based on modality, it is segmented into CVVH, CVVHDF, CVVHD, and SCUF. The CVVH segment is likely to dominate the market during the forecast period. The CVVHDF is likely to dominate the market during the forecast period. The high growth rate of the CVVHDF segment is attributed to its flexibility as compared to other CRRT modalities. The CVVHDF modality also combines the benefits of convection and diffusion for the removal of the solutes, which is another factor supporting the growth of the segment.

Global Continuous Renal Replacement Therapy Market by Age Group

Based on age group, it is segmented into adults, and pediatric/neonates. The adult segment is likely to dominate the market during the forecast period. The increasing demand for invisible braces among adults owing to the large adult population base with AKI, the increase in the hospitalization among the adult population, and the large availability of CRPT systems and disposables of adults undergoing CRRT procedures.

Geographical Analysis of Continuous Renal Replacement Therapy Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is likely to dominate the market during the forecast period. The Europe region is witnessing the fastest growth during the forecast period. The key factors such as rising approval of CRRT products for multiple applications across many European countries coupled with initiatives by the government to increase the awareness about the advancements in renal therapy are likely to play a major role in fueling the growth of the market.

Major Players in Continuous Renal Replacement Therapy Market

The key players studied in the continuous renal replacement therapy market are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China), Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China).

COVID-19 Impact

The COVID-19 pandemic has significantly affected the CRRT market. The surge in the number of COVID cases, combined with the rise in its severity rate, is anticipated to create a potential increase in the incidence of kidney damage. This makes AKI the next emerging healthcare concern after respiratory tract infections among patients with COVID-19. Owing to the pandemic, the demand for renal replacement fluids has raised significantly across the globe. According to an article published by the International Society of Nephrology 2020, countries like China and Italy reported AKI rates as high as 29%. The early initiation of continuous renal replacement therapy (CRRT) is an important step to curbing the increasing incidence of AKI owing to the COVID-19 infection. Still, due to the rapid rise in the demand by healthcare systems, HD and PD exist as alternative dialysis treatment in ICUs, which can have a negative impact on the growth of the CRRT market during this period.

Recent Developments
  • February 2021: DaVita accomplished its first position by including a secure telehealth platform, DaVita Care Connect, into its home dialysis program.
  • December 2020: Medtronic announced the launch of the Carpediem System, the first and only pediatric and neonatal acute dialysis designed to treat patients weighing 2.5-10Kg requiring renal replacement therapy.
  • July 2019: Baxter Internatinal Inc. introduced the Pris Max CRRT system in the US.
  • January 2019: Fresenius Medical Care AG & KGaA announced the launch of the 4008A dialysis machines in India.
Frequently Asked Questions

Q1. How big is the continuous renal replacement therapy market?

Ans. The global continuous renal replacement therapy market size was USD 1.4 Billion in 2021 and is anticipated to reach USD 2.6 Billion in 2031, growing at a rate of 6.3% from 2022 to 2031.

Q2. What is the continuous renal replacement therapy market growth rate?

Ans. The growth rate of the continuous renal replacement therapy market is XX% from 2022 to 2031.

Q3. Which region holds a major market share for the continuous renal replacement therapy market?

Ans. North America holds a major market share of the continuous renal replacement therapy market in 2021.

Q4. Which segment accounted for the largest continuous renal replacement therapy market share?

Ans. By age group, the adult segment accounted for the largest continuous renal replacement therapy market share.

Q5. Who are the key players in the continuous renal replacement therapy market?

Ans. The global continuous renal replacement therapy market report includes players such as Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China), Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China).

Q6. What are the factors driving the continuous renal replacement therapy market growth?

Ans. The major factors driving the growth of the market are the increasing in the prevalence of incidence of acute kidney injury.

Q7. What are the key growth strategies of continuous renal replacement therapy market players?

Ans. The key growth strategies of continuous renal replacement therapy market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the continuous renal replacement therapy market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the continuous renal replacement therapy market during the forecast period.

 

Read More
Single User License

Compression Therapy Market
June, 2022

The global compression therapy market size was valued at USD 3.0 billion in 2021 and it is anticipated to grow at a CAGR of 8.4% during the forecast period to reach up to USD 6.8 billion by 2031.

Compression therapy uses controlled pressure on the lower extremities to increase blood flow and efficiency of the lymphatic and venous system. It is the most established and the most important method of treatment for venous and lymphatic diseases. According to an article published by the National Center for Biotechnology Information (NCBI) in 2018, lymphedema is a pandemic and affects approximately 250 million patients across the globe. The increase in the prevalence of vein disorders such as venous leg ulcer, lymphedema, deep vein thrombosis, etc., the increasing geriatric population, and the rise in the adoption of pressure therapies for the treatment of these vein disorders are the key factors likely to drive the compression therapy market growth during the projection period.

Global Compression Therapy Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$3.0 bn
Market Size in 2031$6.8 bn
Growth Rate (2021-31)8.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Technique, Application, Distribution Channel, and Region
Key CompaniesDJO Global, Inc. (US), BSN medical (US), medi GmbH & Co. KG (Germany), Tactile Medical (US), SIGVARIS (Switzerland), Paul Hartmann AG (Germany), Sanyleg S.r.l. (Italy), 3M (US), ConvaTec Inc. (US), ArjoHuntleigh (Sweden)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The presence of a large target patient population is boosting the market growth of the global compression therapy market. The target population for compression therapy products includes patients suffering from lifestyle-related diseases and vascular diseases, like obesity, diabetes, lymphedema, DVT, and varicose veins. The rising geriatric population across the globe is the primary factor supporting market growth as geriatric individuals are more susceptible to various health conditions. These factors are driving the demand and adoption of various treatment procedures, including compression therapy, among patients. Moreover, compression therapy products are increasingly being preferred as the first line of treatment for major target indications and for post-surgery rehabilitation.

Market Restraints and Challenges

The key factor hindering the market growth is the lack of universally accepted standards for compression products. The lack of uniform international pressure standards for compression therapy garments across the world may cause confusion regarding the selection of the garment for the treatment of various diseases. Worldwide, several standards, including the German RAL, French ASQUL, and British standards, exist with different pressure specifications comprised in each standard. For example, as per the British, French, and German standards, the pressure applied by Class I compression hosiery should be 14–17 mmHg, 15 mmHg, and 18–21 mmHg, respectively.

Adding to that, the US FDA does not have any set standards for compression garments. Currently, the pressure exerted by stockings is determined by manufacturers on the basis of their laboratory measurements owing to the lack of uniform standards for graduated compression stockings worldwide. Moreover, factors such as the elasticity and stiffness of stocking material and the size and shape of a patient’s legs can affect the overall pressure exerted by the garment. Considering the lack of uniform standards in the market, a wide range of products are offered at different price points with varying levels of medical efficacy. The varying efficacy of these products can potentially hamper customer trust in compression therapy, thereby restraining the growth of this market.

Global Compression Therapy Market Segmentation

The report analyses the global compression therapy market based on product, technique, application, distribution channel, and region.

Global Compression Therapy Market by Product

Based on the product, it is segmented into compression garments, compression braces, and compression pumps. The compression garments segment is anticipated to dominate the market during the forecast period. The factors such as the use of compression garments in a wide range of indications, like varicose veins, edema, DVT, and lymphedema, as well as in the management of several chronic conditions are propelling the growth of the market.

Global Compression Therapy Market by Technique

Based on technique, it is segmented into static compression therapy and dynamic compression therapy. Static compression therapy is likely to dominate the market during the forecast period. The key factors such as the presence of a large target population coupled with increasing incidences of sports injuries and accidents are boosting the growth of the market.

Global Compression Therapy Market by Application

Based on application, it is segmented into varicose vein treatment, deep vein thrombosis treatment, lymphedema treatment, leg ulcer treatment, and others. The lymphedema treatment segment is likely to boost the growth of the market. The key factors such as the rising incidence of lymphedema and the high presence of compression therapy products for the treatment and management of lymphedema among end user is boosting the market growth.

Global Compression Therapy Market by Distribution Channel

Based on the distribution channel, it is segmented into pharmacies & retailers, hospitals & clinics, and E-commerce platforms. The e-commerce platforms is likely to boost the growth of the market during the forecast period. The cost advantages of distributing products through e-commerce platforms, a strong and fast-expanding logistical network maintained by e-commerce companies across the globe. The increasing strategic initiatives and investments undertaken by e-commerce companies as well as market players to strengthen their presence across emerging markets are boosting the growth of the market.

Geographical Analysis of Global Compression Therapy Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region accounted for the major market share during the forecast period. The growing number of patients suffering from DVT, varicose veins, and lymphedema coupled with the increasing incidence of sports injuries and the presence of a number of compression therapy product manufacturers in the region are propelling the market growth.

Major Players in Compression Therapy Market

The key players in the global compression therapy market are DJO Global, Inc. (US), BSN medical (US), medi GmbH & Co. KG (Germany), Tactile Medical (US), SIGVARIS (Switzerland), Paul Hartmann AG (Germany), Sanyleg S.r.l. (Italy), 3M (US), ConvaTec Inc. (US), ArjoHuntleigh (Sweden), Julius Zorn GmbH (Germany), Bio Compression Systems, Inc. (US), Cardinal Health, Inc. (US), and Smith & Nephew plc (UK).

COVID-19 Impact

The current global COVID-19 pandemic has significantly impacted markets across multiple sectors and industries such as healthcare, oil & petroleum, aeronautics & defense, and food & beverage. The majority of these industries are witnessing a period of uncertainty in terms of global economic conditions, the regional impact of the pandemic on businesses, government laws and preventive regulations, demand from end users, and challenges faced in the supply chain and logistics. Owing to that, key businesses and market players are forced to shift focus from long-term growth strategies to short-term sustainability tactics that have led to changes in business operations such as manufacturing, supplying, and consumer communication in certain sectors of the global economy. The healthcare sector is at the epicenter of this global pandemic challenge and is anticipated to have major long-term consequences. This is likely to compel countries and key market players to undergo essential healthcare reforms once the crisis is eventually under control or has faded. The private healthcare sector is facing twice the burden—investing additional manpower, equipment, consumables, and other resources to ensure 100% preparedness for safety in hospitals and the eventual treatment of patients alongside the sharp drop in out-patient footfall, elective surgeries, and international patients. Additionally, hospitals are affected by this pandemic as a clear lack in the number of healthcare professionals is being witnessed in developed as well as developing countries. The pandemic has also affected the orthopedics field since doctors are not adequately able to concentrate on regular patients since they are being redeployed for treating COVID-19 patients. Owing to that, performing orthopedics and trauma surgeries has become a significant challenge with the non-availability of hospital staff and operation facilities.

Recent Developments

  • May 2021, FDA has given clearance to Koya Medical’s compression therapy system for lower extremities.
  • April 2021, Essity acquired by ABIGO Medical. The acquisition added to the company’s wound care product portfolio.
  • April 2021, DJO acquired MedShape, Inc. This acquisition will strengthen DJO’s portfolio of fracture fixation, joint fusion, and soft tissue injury repair products, which utilize biomaterial technologies designed to improve patient outcomes.
  • February 2021, De Royal signed a USD 1.2 million agreement with Tyndall and RCSI SWaT researchers. The primary objective of this partnership was to transform compression wound therapy.
  • November 2020, Theragun. Inc. had acquired RP Sports, one of the leaders in clinical pneumatic compression. Theragun, Inc. has acquired RP Sport’s groundbreaking clinical technology product line, Recovery Pump.
  • July 2020, AIROS Medical Inc., announced the launch of its updated compression therapy products. The company’s new AIROS 6 Sequential Compression Therapy device and Arm Plus garments had been approved by the FDA for the first time in three years.
  • June 2020, Medi GmbH & Co. KG launched mediven cosy 450, which added to its flat-knit compression portfolio.
Frequently Asked Questions

Q1. How big is the compression therapy market?

Ans. The global compression therapy market size was USD 3.0 Billion in 2021 and is anticipated to reach USD 6.8 Billion in 2031, growing at a rate of 8.4% from 2022 to 2031.

Q2. What is the compression therapy market growth rate?

Ans. The growth rate of the compression therapy market is 8.4% from 2022 to 2031.

Q3. Which region holds a major market share for the compression therapy market?

Ans. North America holds a major market share of the compression therapy market in 2021.

Q4. Which segment accounted for the largest compression therapy market share?

Ans. By product, the compression garment segment accounted for the largest compression therapy market share.

Q5. Who are the key players in the compression therapy market?

Ans. The global compression therapy market report includes players such as DJO Global, Inc. (US), BSN medical (US), medi GmbH & Co. KG (Germany), Tactile Medical (US), SIGVARIS (Switzerland), Paul Hartmann AG (Germany), Sanyleg S.r.l. (Italy), 3M (US), ConvaTec Inc. (US), ArjoHuntleigh (Sweden), Julius Zorn GmbH (Germany), Bio Compression Systems, Inc. (US), Cardinal Health, Inc. (US), and Smith & Nephew plc (UK).

Q6. What are the factors driving the compression therapy market growth?

Ans. The major factors driving the growth of the market are the increasing number of orthopedic procedures.

Q7. What are the key growth strategies of compression therapy market players?

Ans. The key growth strategies of compression therapy market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the compression therapy market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the compression therapy market during the forecast period.

Read More
Single User License

Companion Diagnostics Market
June, 2022

The global companion diagnostics market was valued at USD 5.9 billion in 2021 and it is anticipated to grow at a CAGR of 11.8% during the forecast period to reach up to USD 18.0 billion by 2031.

Companion diagnostics is a medical device used along with therapeutic drugs to analyze the effect & applicability of drugs on a specific human body. Companion diagnostics are developed along with drugs for selecting or excluding groups of patients based on the characteristics of which they respond to the therapy. This device helps the healthcare professional to analyze whether a particular treatment is beneficial to the patient.

Global Companion Diagnostics Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$5.9 bn
Market Size in 2031$18.0 bn
Growth Rate (2021-31)11.8%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct & Services, Technology, Indication, End User, and Region
Key CompaniesF. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor such as the growing requirement for targeted medicine is boosting the growth of the market. With advances in genetic sequencing and genomics, it is now extensively believed that drugs can show varying outcomes in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering ‘the right drug, at the right time, at the right dose, for the right person. Pharmaceutical and biopharmaceutical companies are regularly attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further boosted the growth of the companion diagnostics market.

Similarly, the increasing demand for next-generation sequencing is also refueling the market during the forecast period. NGS-based companion diagnostic target to unlock molecular information from each patient’s tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of various types of cancers. The various technological advancements in NGS also provide market players with an immediate competitive edge over players providing other technologies such as PCR, ICH, and ISH. Owing to that, major market players are focusing on developing companion diagnostic products based on NGS.

Market Restraints and Challenges

The key factor hindering the market growth is the lack of awareness of companion diagnostics testing. It is important to build awareness amongst patients, clinicians, and the public regarding the importance of clinical trials. To increase awareness among clinicians, providing special access to the reputable, evidence-based latest information on these new cancer medicines can be helpful. To improve public awareness, increasing access to a common and trusted source of truth is essential. Several publishing houses coupled with industry players provide monthly journals and information leaflets. Stakeholders have also focused on awareness initiatives to ensure patients and providers can access and understand the benefits of companion diagnostics.

Global Companion Diagnostics Market Segmentation

The report analyses the global companion diagnostics market based on product & services, technology, indication, end user, and region.

Global Companion Diagnostics Market by Products & Services

Based on products & services, it is segmented into assays, kits & reagents, software and services. The assay, kits & reagents accounted for the largest share of the companion diagnostics market in 2021. The factors such as the availability of a wide range of products coupled with the increasing use of assays and kits in different therapeutic areas are boosting the growth of the market.

Global Companion Diagnostics Market by Technology

Based on technology, it is segmented into a polymerase chain reaction, next-generation sequencing, In situ hybridization, immunohistochemistry, and others. The PCR segment is likely to dominate the market during the forecast period. Ease of use coupled with the widespread availability of PCR kits & reagents in companion diagnostic testing and growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes are some factors boosting the market growth.

Global Companion Diagnostics Market by Indication

Based on indication, it is segmented into cancer, cardiovascular diseases, neurological diseases, infectious diseases, and others. The cancer segment is likely to dominate the market during the forecast period. Factors such as the growing role of companion diagnostics in the personalized medicine treatment for cancer coupled with the increasing utility of biomarkers in the diagnosis of cancer are boosting the market growth.

Global Companion Diagnostics Market by End User

Based on the end user, it is segmented into pharmaceutical & biopharmaceutical companies, reference laboratories, contract research organizations, and others. The pharmaceutical & biopharmaceutical companies segment is likely to dominate the market during the forecast period. The key factors such as the growing use of companion diagnostics owing to their increasing prominence in drug development coupled with the increasing importance of companion diagnostic biomarkers are boosting the market growth.

Geographical Analysis of Companion Diagnostics Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is likely to dominate the market during the forecast period. The key factors such as the presence of many leading companion diagnostic vendors & national clinical laboratories coupled with the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

Major Players in Companion Diagnostics Market

The key players of the companion diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

COVID-19 Impact

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the globe. The raised pressure owing to the rising rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments for treating patients with COVID-19. The COVID-19 outbreak led to curfews and lockdown across the globe, leading to many diagnostic and treatment procedures had been cancelled or postponed around the world, comprising as many as 2.3 million cancer surgeries according to one study. Clinical trials in oncology have also been affected, with about 170 studies suspended owing to Covid-19, according to a report by Evaluate Vantage. It has mild-moderately affected the growth of the companion diagnostics market. As stringencies with respect to curfews and social distancing become more liberal, the demand is expected to grow, creating a deficit in the market. Still, a resurgence in testing numbers is being seen as countries gradually ease restrictions on movement. Additionally, the demand for companion diagnostic tests is on the rise for the early detection and screening of chronic diseases. These tests also help reduce the side-effects of drugs, improve patient outcomes, provide high diagnostic accuracy and specificity, reduce pharmacotherapy variability, and identify the most-effective targeted therapy options. They are also associated with higher drug development success.

Recent Developments
  • May 2021: QIAGEN N.V. (Germany) expanded the therascreen KRAS Kit.
  • May 2020: Medical and Biological Laboratories Co. Ltd., announced that it has launched an in vitro diagnostic kit for the genetic disease Spinal Muscular Atrophy. The MEBCDX AAV9 test kits, was licensed from Quest Diagnostics.
  • May 2019: QIAGEN N.V. launched the therascreen PIK3CA RGQ PCR kit in PIQRAY therapy in the U.S. to enhance its product portfolio in the Companion Diagnostics Market.
  • April 2019: Roche Diagnostics acquired TIB Molbiol Group. This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
Frequently Asked Questions

Q. How big is the companion diagnostics market?

Ans. The global companion diagnostics market size was USD 5.9 Billion in 2021 and is anticipated to reach USD 18.0 Billion in 2031, growing at a rate of 11.8% from 2022 to 2031.

Q. What is the companion diagnostics market growth rate?

Ans. The growth rate of the companion diagnostics market is 11.8% from 2022 to 2031.

Q. Which region holds a major market share for the companion diagnostics market?

Ans. North America holds a major market share of the companion diagnostics market in 2021.

Q. Which segment accounted for the largest companion diagnostics market share?

Ans. By technology, the PCR segment accounted for the largest companion diagnostics market share.

Q. Who are the key players in the companion diagnostics market?

Ans. The global companion diagnostics market report includes players such as F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Q. What are the factors driving the companion diagnostics market growth?

Ans. The major factors driving the growth of the market are the increasing demand for next-generation sequencing.

Q. What are the key growth strategies of companion diagnostics market players?

Ans. The key growth strategies of companion diagnostics market players are product launch and product approval.

Q. Which region will provide more business opportunities for the companion diagnostics market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the companion diagnostics market during the forecast period.

Read More
Single User License

Companion Animal Pharmaceuticals Market
June, 2022

The global companion animal pharmaceuticals market was valued at USD 12.9 billion in 2021 and it is anticipated to grow at a CAGR of 7.6% during the forecast period to reach up to USD 26.8 billion by 2031.

The rising adoption of pet animals due to growing urbanization and an increase in the number of nuclear families is among the primary market growth factors. A growing focus on animal health along with surging demand for pet insurance, especially in developed countries will augment the market expansion. The consistent rise in the number of diseases affecting animals is, in turn, generating demand for companion animal drugs. Additionally, industrial growth is attributable to the increasing incidence of zoonotic and food-borne diseases across the globe.

Global Companion Animal Pharmaceutical Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$12.9 bn
Market Size in 2031$26.8 bn
Growth Rate (2021-31)7.6%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredIndication, Animal Type, Distribution Channel, and Region
Key CompaniesZoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors such as the growing prevalence of zoonotic diseases is boosting the market growth during the forecast period. Some pathogens, such as zoonotic, can be transmitted from animals to humans. Examples of zoonotic diseases include rabies, salmonellosis, plague, brucellosis, and Lyme disease. Animals also share our susceptibility to certain diseases and environmental hazards and can serve as an early warning for potential human infections. Over the past two decades, the incidence of zoonotic diseases has increased across the globe, primarily as a result of the increased pet population. According to the International Livestock Research Institute (ILRI), 13 zoonoses cause 2.4 billion cases of human diseases and 2.2 million deaths every year. Toxoplasmosis—which is transmitted via cat feces—is quite common, with 10–20% of the UK population and 22% of the US population expected to carry the parasite as cysts. Cats with chronic bacteremia are primarily infected through saliva, and there is a high risk of transmittance from young adult cats. Although cats are asymptomatic carriers, weaker individuals can develop generalized infections. Many of the emerging and re-emerging infectious disease threats are vector-borne diseases transferred to animals and humans from arthropods.

Market Restraints and Challenges

The increasing pet care costs is likely to hinder the market growth during the forecast period. According to the APPA National Pet Owners Survey (2019), the average household in the US spent USD 731 on the routine doctor and surgical visits for dogs in 2019, a rise of 47% as compared to a decade ago. Similarly, USD 427 was spent on the routine doctor and surgical visits for cats in 2019. In Germany, the annual veterinary cost is ~USD 162.9 (EUR 140) per dog and USD 75.61 (EUR 65) per cat. In Japan, pet owners spend around USD 2,000–3,000 (JPY 200,000–300,000) annually on pet health. While the pet insurance market is expanding, the number of animals covered for treatments is still very less. As a result, animal owners generally bear the majority of the cost of treatments. Also, according to the Society for Practicing Veterinary Surgeons, coupled with the increasing pet insurance, the cost of veterinary treatment is rising by about 12% a year.

Global Companion Animal Pharmaceutical Market Segmentation

The report analyses the global companion animal pharmaceutical market based on indication, animal type, distribution channel, and region.

Global Companion Animal Pharmaceutical Market by Indication

Based on indication, it is segmented into infectious diseases, dermatological diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic segment is likely0 to dominate the market during the forecast period. The increasing prevalence of arthritis coupled with the rising need for advanced orthopedic drugs, and the growing pet population are some key factors boosting the market growth.

Global Companion Animal Pharmaceutical Market by Animal Type

Based on animal type, it is segmented into dogs, cats, horses, and others. The dog segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing dog’s population coupled with a rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe are boosting the market growth.

Global Companion Animal Pharmaceutical Market by Distribution Channel

Based on the distribution channel, it is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospital segment is estimated to dominate the market during the forecast period. The key factors such as the animal parasiticides and antibiotics in hospital settings coupled with increasing incidence of infectious diseases, a growing number of veterinary hospitals, growing ownership of companion animals and increasing veterinary expenditure, and growing awareness about animal health in developing countries are some factors driving the growth of the segment.

Geographical Analysis of Companion Animal Pharmaceutical Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is likely to hold the major share of the market during the forecast period. The factors attributing to the growth of the market are a well-established base of animal health industries coupled with increasing incidences of parasitic infections, a large number of hospitals and clinics, a growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is refueling the market growth.

Major Players in Companion Animal Pharmaceutical Market

The key factors in the global companion pharmaceutical market are Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

COVID-19 Impact

Since the beginning of 2020, an increasing number of countries across the world have shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, creating impediments for international trade and transportation. This disrupted the supply chain for the companion animal pharmaceuticals market, temporarily leading to a decline in the demand for these products. According to the American Veterinary Medical Association (AVMA), there is no evidence that animals are playing a significant epidemiological role in the spread of human COVID-19 infections; conversely, because animals and people can sometimes share diseases, it is still recommended that people with suspected/confirmed infections limit contact with animals and take precautions while handling pets or animals.

Recent Developments
  • February 2020, Vetoquinol acquired Canadian rights for the Profender product family from Elanco Animal Health. The acquisition is poised to impact the company’s revenue and offer business development opportunities in untapped economies.
  • September 2020, Virbac acquired a range of Tilapia vaccines from Ictyogroup to distribute and market them across the globe.
  • August 2020, Elanco Animal Health Incorporated announced that it has acquired Bayer Animal Health. The transaction was valued at USD 6.89 billion. This development helped the economy to expand itself in the durable animal health industry.
  • June 2020, Merck invested USD 100 million in facility expansion and enhancement efforts in its US manufacturing site in De Soto, Kansas. This site also comprises an additional expansion of the vaccine production facility, so enhancing its manufacturing and capabilities.
  • February 2020, Zoetis received FDA approval for Simparica Trio.
  • February 2019, Zoetis launched Eradia, an antibiotic for dogs, in Europe.
Frequently Asked Questions

Q. How big is the companion animal pharmaceutical market?

Ans. The global companion animal pharmaceutical market size was USD 12.9 Billion in 2021 and is anticipated to reach USD 26.8 Billion in 2031, growing at a rate of 7.6% from 2022 to 2031.

Q. What is the companion animal pharmaceutical market growth rate?

Ans. The growth rate of the companion animal pharmaceutical market is 7.6% from 2022 to 2031.

Q. Which region holds a major market share for the companion animal pharmaceutical market?

Ans. North America holds a major market share of the companion animal pharmaceutical market in 2021.

Q. Which segment accounted for the largest companion animal pharmaceutical market share?

Ans. By animal type, the dog segment accounted for the largest companion animal pharmaceutical market share.

Q. Who are the key players in the companion animal pharmaceutical market?

Ans. The global companion animal pharmaceutical market report includes players such asZoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

Q. What are the factors driving the companion animal pharmaceutical market growth?

Ans. The major factors driving the growth of the market are the increasing prevalence of zoonotic diseases.

Q. What are the key growth strategies of companion animal pharmaceutical market players?

Ans. The key growth strategies of companion animal pharmaceutical market players are product launch and product approval.

Q. Which region will provide more business opportunities for the companion animal pharmaceutical market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the companion animal pharmaceutical market during the forecast period.

Read More
Single User License

Brain Monitoring Market
June, 2022

The global brain monitoring market size was USD 5.4 billion in 2021 and it is anticipated to reach USD 10.1 billion in 2031, growing at a rate of 7.2% from 2022-2031.

Brain monitoring helps clinicians in monitoring the condition of the brain under the influence of anesthesia through bilateral data acquisition and processing of the EEG signals. Brain monitoring devices are used to monitor and diagnose neurological conditions by exploring the structure and function of the brain. This process involves the use of several brain monitoring devices. At present, there is an increase in the demand for electroencephalography devices among healthcare providers.

Brain Monitoring Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$5.4 bn
Market Size in 2031$10.1 bn
Growth Rate (2021-31)7.2%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct Type, Procedure, Application, and Region
Key CompaniesAdvanced Brain Monitoring, Inc., CAS Medical Systems, Inc., Compumedics Ltd., General Electric Company (GE Healthcare), Koninklijke Philips N.V. (Philips Healthcare), Medtronic Plc., Natus Medical Incorporated, Neural Analytics, Inc., Siemens AG, Cadwell Laboratories, Neurosoft Limited, Elekta A.B., InfraSacn, Inc., BrainScope Company, Inc.
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The major factor boosting the growth of the market is the increasing incidence and prevalence of neurological disorders. The global incidence and prevalence of neurological disorders, like dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuro infections, stroke, and cerebral palsy, have increased significantly during the last few years. Brain disorders, which comprise a combination of developmental, psychiatric, and neurodegenerative diseases, are a growing cause of morbidity worldwide. This can mainly be attributed to the growing geriatric population (by 2050, more than 20% of the global population is expected to be aged over 65 years). The American Medical Association (AMA) anticipates that at least 60% of individuals aged 65 years and above will be living with more than one chronic condition by 2030.

The rising incidences of these neurological disorders have made it extremely important to monitor brain and neurological function. Many neurological disorders and conditions are progressive, and their risk increases with age. Adding to that, the prevalence of other diseases and conditions, such as sickle-cell diseases and cardiac disorders, is also increasing. Cardiac procedures may sometimes affect the normal functioning of the brain, which is another factor driving the demand for brain monitoring devices.

Market Restraints & Challenges

One of the primary challenges in the growth of the global brain monitoring market is the high cost of complex brain monitoring procedures and devices. The high cost of brain monitoring surgeries and devices is a primary factor restraining the global brain monitoring market, majorly in developing countries with poor reimbursement policies. Brain monitoring devices are highly complex, and the procedures involving the use of these devices are generally expensive. For example, the average cost of a standard EEG is ~USD 200–700; this procedure can cost as high as USD 3,000 for extended monitoring. A dual-channel TCD costs approximately USD 3,000–3,200, and an ICP monitor costs approximately USD 340–500. Similarly, a single MEG system costs roughly USD 2.5–3 million. Owing to the high price, healthcare facilities, even in countries that show wide adoption of high-tech medical equipment, find it difficult to procure MEG devices. Moreover, the maintenance cost and other associated indirect expenses increase the total cost of ownership of these devices, so limiting their adoption.

Global Brain Monitoring Market Segmentation

The report analyses the brain monitoring market based on product type, procedure, application, and region.

 

Global Brain Monitoring Market by Product Type

 

On the basis of product type, it is segmented into electroencephalography devices, magnetoencephalography devices, transcranial doppler devices, intracranial pressure monitors, cerebral oximeters, magnetic resonance imaging devices, computerized tomography devices, sleep monitoring devices, electromyography devices, and accessories. The electroencephalography devices segment is likely to dominate the market during the forecast period. The surge in demand for the diagnosis of critical disorders such as epilepsy has further influenced companies to focus on the development of brain monitoring EEG devices.

Global Brain Monitoring Market by Procedure

On the basis of procedure, it is segmented into invasive and non-invasive. The non-invasive segment accounted for the fastest growth during the forecast period. The key factors such as rise in incidences of traumatic brain injuries coupled with a high acceptance rate of minimally invasive devices, and a low risk of mortality. This increases the demand for these products which propels the market growth.

Global Brain Monitoring Market by Application

On the basis of application, it is segmented into epilepsy, dementia, parkinson’s disease, huntington’s disease, headache disorders, stroke, traumatic brain injuries, sleep disorders, and other diseases. The epilepsy segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing geriatric population and the rise in the prevalence of neurological disorders are boosting the growth of the market.

Geographical Analysis of Global Brain Monitoring Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global brain monitoring market. The key factors such as growing incidences of neurological diseases, a growing number of clinical trials of brain monitoring products, and the availability of medical reimbursement in the US.

Major Players of the Global Brain Monitoring Market

The global brain monitoring market report includes players such as Advanced Brain Monitoring, Inc.CAS Medical Systems, Inc. , Compumedics Ltd. , General Electric Company (GE Healthcare) , Koninklijke Philips N.V. (Philips Healthcare) , Medtronic Plc. , Natus Medical Incorporated , NovaSignal , Siemens AG , Cadwell Laboratories , Neurosoft Limited , Elekta A.B. , InfraSacn, Inc. , BrainScope Company, Inc. among others.

COVID-19 Analysis

The state of urgency to combat the outbreak has led to a significant increase in the demand for remote monitoring and patient engagement solutions. Most hospitals/healthcare facilities are currently trying to expand patient monitoring to home care settings or other temporary setups with an aim to provide optimal care. COVID-19 has led to a significant surge in demand for ventilators, and manufacturers are currently focusing their efforts to meet the increasing need for ventilators. Comprising other respiratory devices, in contrast to the brain monitoring business, particularly owing to the focus of hospitals on setting up COVID-19 specific ICUs, along with the temporary suspension of manufacturing sites in highly affected regions worldwide.

Recent Developments
  • September 2021, NeuroWave Systems Inc. announced the FDA clearance of its Neuro SENSE NS-901 Monitor- a new generation brain function monitor for assessing the adequacy of anesthesia and sedation in clinical settings.
  • November 2021, Brain Scientific received FDA clearance for Next-Gen Neuro Cap EEG Headset, and advanced electroencephalogram electrodes array used to obtain rapid EEG’s in routine clinical and research settings where the recording of STAT EEG’s is desired.
  • February 2020, Compumedics announced milestone US FDA approval for the Orion Life Span MEG.
Brain Monitoring Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global brain monitoring market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of aspects that boost and restrict the development of the market is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future brain monitoring market potential from 2021 to 2031 in terms of revenue.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global brain monitoring industry.
Frequently Asked Questions

Q. How big is the brain monitoring market?

Ans. The global brain monitoring market size was USD 5.4 billion in 2021 and is anticipated to reach USD 10.8 billion in 2031, growing at a rate of 7.2% from 2022 to 2031.

Q. What is the brain monitoring market growth rate?

Ans. The growth rate of the brain monitoring market is 7.2% from 2022 to 2031.

Q. Which region holds a major market share for the brain monitoring market?

Ans. North America holds a major market share of the brain monitoring market in 2021.

Q. Which segment accounted for the largest brain monitoring market share?

Ans. By application, the epilepsy segment accounted for the largest brain monitoring market share

Q. Who are the key players in the brain monitoring market?

Ans. The global brain monitoring market report includes players such as Advanced Brain Monitoring, Inc., CAS Medical Systems, Inc, Compumedics Ltd, General Electric Company (GE Healthcare), Koninklijke Philips N.V. (Philips Healthcare), Medtronic Plc., Natus Medical Incorporated, Neural Analytics, Inc., Siemens AG, Cadwell Laboratories, Neurosoft Limited, Elekta A.B., InfraSacn, Inc. and BrainScope Company, Inc.

Q. What are the factors driving the brain monitoring market growth?

Ans. The major factors driving the growth of the market are the increasing volume of surgeries and the growing prevalence of severe trauma injuries.

Q. What are the key growth strategies of brain monitoring market players?

Ans. The key growth strategies of brain monitoring market players are product launch and product approval.

Q. Which region will provide more business opportunities for the brain monitoring market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for brain monitoring market during the forecast period

Read More
Single User License

Cold Plasma Market
June, 2022

The global cold plasma market was valued at USD 1.9 billion in 2021 and it is projected to reach up to USD 5.7 billion by 2031, at a CAGR of 10.5% during the forecast period.

Cold plasma, also referred to as non-equilibrium plasma or non-thermal plasma is a classification of plasma, and is considered the fourth state of matter. It has numerous applications in bioengineering, medicine, and therapeutics. Cold plasma is used for sterilization of biomedical surfaces, treatment of living biological tissues, and surface modification of biomedical devices and materials, owing to its antimicrobial & bactericidal properties.

The global cold plasma market is driven by less requirement of water for the process reducing the wastewater treatment cost; medical applications, such as enhancement of tissue repair, control of bleeding, destruction of cancer cells; and its application in packaging industries. Still, the huge capital incurred for implementing cold plasma technology is a key hindrance for the market. On the other hand, the growing need for medical research for developing treatment of lung, bladder, skin, and breast cancer offer lucrative opportunities for market growth.

Global Cold Plasma Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$1.9 bn
Market Size in 2031$5.7 bn
Growth Rate (2021-31)10.5%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredApplication, Regime, and Region
Key CompaniesApyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries (US), Acxys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors such as the benefits of cold plasma technology are likely to boost the growth of the cold plasma market. Cold plasma technology has diverse applications in several industries. This processing method possesses many advantages, like low water and energy consumption, minimal fiber damage, reduced flammability, low chemical consumption, improved wettability, low cost, and a worker-friendly nature. Also, cold plasma technologies do not require onsite storage of supply chemicals or large volumes of processing water, either for implementation or in post-treatment rinsing. Their advantages, as compared to the currently used alternatives in application industries, have served to boost the adoption of cold plasma techniques.

Similarly, the application of cold plasma in infection prevention and prolonging the life of PPE is also refueling the growth of the market. Cold plasma may be used in the prevention of infectious diseases and nosocomial infections as it kills highly stable multi-resistant microbes. In the COVID-19 pandemic, protective clothing and sterile textiles are in short supply. Treatment with cold plasma or ozone-generating plasma can prolong the use of clothing. It can also help in the hydrophilization process in the textile industry for gloves, PPE kits, and masks to reduce microorganisms. Plasma treat, one of the leading players in the cold plasma market, has developed a prototype cleaning station that provides solutions for disinfecting protective clothing.

Market Restraints and Challenges

The major factor hindering the market growth is high capital investment. Before investing, companies always analyze the benefits of technology with regard to their investment and the time taken to recover that cost, considering their budget. Cold plasma technologies are capital-intensive as the equipment used in these coating technologies, such as vacuum equipment, are very costly and require special operating conditions, such as reduced temperatures and controlled vacuum conditions for operation.

Global Cold Plasma Market Segmentation

The report analyses the global cold plasma market based on industry, regime, and region.

Global Cold Plasma Market by Industry

Based on industry, it is segmented into polymer & plastic industry, textile industry, electronics & semiconductors industry, food & agriculture industry, and medical industry. The medical industry segment is likely to dominate the market during the forecast period. The advantages of cold plasma treatment coupled with minimal side-effects are propelling the market growth of the segment.

Global Cold Plasma Market by Regime

Based on the regime, it is segmented into atmospheric cold plasma, and low pressure plasma. The low pressure plasma segment is likely to dominate the market during the projection period. The key factors such as bacterial activity coupled with minimal surface ablation is boosting the market growth.

Geographical Analysis of Cold Plasma Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is anticipated to dominate the market during the forecast period. The key factors such as increasing demand for decontaminated frozen food coupled with growing manufacturing facilities of textiles and the rising production of polymers are refueling the market growth during the forecast period.

Major Players in Cold Plasma Market

The key players in the global cold plasma market are Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries (US), Acxys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), Terraplasma GmbH (Germany), Molecular Plasma Group (Germany), CINOGY GmbH (Germany), Advanced Plasma Solutions (US), UNIQAIR Technologies (US), PlasmaLeap Technologies (Australia), US Medical Innovations (US), and COMET Plasma Control Technologies (US).

COVID-19 Impact

The cold plasma market is anticipated to be significantly impacted by the Covid-19 pandemic in 2020-2021. However, there could be possible disruptions in the industries such as electronics & semiconductors, textile, polymer & plastic, food & agriculture, and medical during the period of lockdown and movement restrictions imposed across the globe to control the virus spread and flatten the curve. Social distancing protocols and quarantine measures have reduced the demand for textiles, apparel, semiconductors & electronic appliances, large-scale farming practices, and non-essential services have been put off till the post lockdown period.

Recent Developments
  • April 2020, Relyon plasma GmbH launched atmospheric plasma system, piezobrush PZ3.
  • February 2020, Hennikar plasma signed a partnership with Irida, this helped the company to strengthen its geographic presence in Spain
  • March 2019, Nordson Corporation launched Flex TRAK-SHS automated plasma treatment system. The FlexTRAK-SHS system’s advanced automation enables simultaneous strip buffering and plasma processing for higher chamber utilization normally despite being fully submerged for long periods, and the outer case breached.
  • February 2019, P2i launched Drunkable, a system-level waterproofing solution that enables a smartphone to operate normally despite being fully submerged for long periods, and the outer case breached.
  • November 2019, Europlasma launched a nanocoating product Plasmaguard.
Frequently Asked Questions

Q. How big is the cold plasma market?

Ans. The global cold plasma market size was USD 2.1 Billion in 2021 and is anticipated to reach USD 5.7 Billion in 2031, growing at a rate of 10.5% from 2022 to 2031.

Q. What is the cold plasma market growth rate?

Ans. The growth rate of the cold plasma market is 10.5% from 2022 to 2031.

Q. Which region holds a major market share for the cold plasma market?

Ans. North America holds a major market share of the cold plasma market in 2021.

Q. Which segment accounted for the largest cold plasma market share?

Ans. By regime, the low pressure cold plasma segment accounted for the largest cold plasma market share.

Q. Who are the key players in the cold plasma market?

Ans. The global cold plasma market report includes players such as Apyx Medical Corporation (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries (US), Acxys Plasma Technologies (France), Plasmatreat (Germany), Tantec A/S (Denmark), Europlasma (Belgium), Thierry Corporation (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), Terraplasma GmbH (Germany), Molecular Plasma Group (Germany), CINOGY GmbH (Germany), Advanced Plasma Solutions (US), UNIQAIR Technologies (US), PlasmaLeap Technologies (Australia), US Medical Innovations (US), and COMET Plasma Control Technologies (US).

Q. What are the factors driving the cold plasma market growth?

Ans. The major factors driving the growth of the market are the increasing R&D.

Q. What are the key growth strategies of cold plasma market players?

Ans. The key growth strategies of cold plasma market players are product launch and product approval.

Q. Which region will provide more business opportunities for the cold plasma market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the cold plasma market during the forecast period.

Read More
Single User License

Cold Pain Therapy Market
June, 2022

The global cold pain therapy market was valued at USD 1.8 billion in 2021 and it is anticipated to grow at 5.9% CAGR during the projection period to reach up to USD 3.2 billion by 2031.

Cold pain therapy includes the usage of cold materials to relieve pain. Cryotherapy is generally used as an essential injury management skill. Ice packs are applied to inflammations and injuries to help reduce pain and swelling. Studies suggest that cold compression slows blood flow to the injury, thereby reducing pain, inflammation, and muscle spasm. Ice packs are effective, inexpensive, and drugless methods to relieve pain from sprains, strains, bruises, tendinitis, and swelling caused due to trauma to superficial tissues. Cold packs, used on inflammations act as a primary analgesic to relieve pain. Cold pain therapy is primarily used on fresh injuries such as ligament sprains, muscle sprains, and severe bruises. This therapy is used for chronic overuse or tissue fatigue injuries such as carpal tunnel syndrome, tennis elbow, supraspinatus tendinitis, iliotibial band syndrome, patellofemoral pain syndrome, and plantar fasciitis.

Global Cold Pain Therapy Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$1.8 bn
Market Size in 2031$3.2 bn
Growth Rate (2021-31)5.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Application, Distribution Channel, and Region
Key CompaniesBeiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the market growth is increasing the number of hip and knee surgeries. There has been observed that aging-related changes in the musculoskeletal system increase the propensity to osteoarthritis (OA), and the severity of the disease is closely related to other OA risk factors such as joint injury, obesity, genetics, and anatomical factors that affect joint mechanics. OA is not an inevitable consequence of growing old, although older age is the greatest risk factor for OA. The market demand for surgical treatment, including joint replacement surgery (hip and knee replacement), is expected to increase significantly, owing to the rapidly increasing aging population across the globe.

Similarly, the increasing adoption of analgesic patches is also refueling the market growth. Analgesic patches feature a transdermal drug delivery system, which is a non-invasive mode of medication delivery through the skin. Patches deliver an analgesic drug at a fixed rate across the dermis, while placed on the skin. The use of analgesic patches through transdermal drug delivery systems offers certain advantages over oral medications.

Market Restraints and Challenges

The key factor hindering the market growth is the growing use of low-priced analgesic pills for immediate pain relief. The most widely used OTC analgesic drugs are paracetamol or acetaminophen, ibuprofen, and aspirin. These drugs are widely available at lower costs. This, combined with the lack of awareness of the adverse effects of painkillers, is a key factor contributing to the high adoption of analgesic pills for immediate pain relief. Additionally, owing to the lack of awareness about new therapies for pain management, the availability of low-priced generic versions of drugs, and increasing health concerns are contributing to the high usage of analgesic pills which cause a high adoption of OTC drugs by customers in emerging nations.

Global Cold Pain Therapy Market Segmentation

The report analyses the global cold pain therapy market based on product, application, distribution channel, and region.

Global Cold Pain Therapy Market by Product

Based on product, it is segmented into OTC products, and prescription products. The OTC product segment is likely to dominate the market during the forecast period. The easy accessibility of OTC products in retail and online pharmacies is boosting the growth of the OTC segment in the global cold pain therapy market.

Global Cold Pain Therapy Market by Application

Based on application, it is segmented into musculoskeletal disorders, sports medicine, post-operative therapy, and post-trauma therapy. The musculoskeletal disorders segment is anticipated to dominate the market during the forecast period. Factors such as immediate pain relief provided by cold pain therapy products are boosting the market growth during the forecast period.

Global Cold Pain Therapy Market by Distribution Channel

Based on the distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and e-pharmacies. The retail pharmacies segment is likely to dominate the market during the forecast period. The easy availability of all the essential cold pain therapy products in retail pharmacies is boosting the growth of this market during the forecast period.

Geographical Analysis of Global Cold Pain Therapy Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American region is likely to dominate the market during the forecast period. The growing use of sports medicine is likely to dominate the market during the forecast period.

Major Players in Cold Pain Therapy Market

The key players in the global cold pain therapy market are Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).

COVID-19 Impact

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the globe. The supply chains have faced major disruptions worldwide and adjusted to the ongoing needs and demands for cold therapy products among people living with musculoskeletal and arthritis pain. Several rehabilitation centers and pain treatment centers were shut down abruptly owing to the pandemic, which has lowered the access to cold pain therapy products across and within populations with a higher burden of musculoskeletal pain. The pain management product manufacturers have faced challenges in terms of delivering cold therapy devices through different modes due to the length of lockdowns.

Recent Developments
  • June 2021, Hisamitsu Pharmaceutical Co., Inc. launched Air Salonpas Z, an analgesic and anti-inflammatory spray for muscle pain, bruises, and sprains, among other conditions.
  • November 2020, Beiersdorf AG invested USD 72.9 million (EUR 60 Million) in Hamburg to develop technological centers for strengthening its R&D unit.
  • September 2019, Rohto Pharmaceutical announced the launch of an advanced technology research laboratory at the Hong Kong Science Park in New Territory, Hong Kong.
Frequently Asked Questions

Q. How big is the cold pain therapy market?

Ans. The global cold pain therapy market size was USD 1.8 Billion in 2021 and is anticipated to reach USD 3.2 Billion in 2031, growing at a rate of 5.9% from 2022 to 2031.

Q. What is the cold pain therapy market growth rate?

Ans. The growth rate of the cold pain therapy market is 5.9% from 2022 to 2031.

Q. Which region holds a major market share for the cold pain therapy market?

Ans. North America holds a major market share of the cold pain therapy market in 2021.

Q. Which segment accounted for the largest cold pain therapy market share?

Ans. By application, the musculoskeletal disorders segment accounted for the largest cold pain therapy market share.

Q. Who are the key players in the cold pain therapy market?

Ans. The global cold pain therapy market report includes players such as Beiersdorf AG (Germany), DJO Global, Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Össur (Iceland), Johnson & Johnson (US), Pfizer (US), Sanofi (France), Rohto Pharmaceutical (Japan), 3M (US), Cardinal Health Inc. (US), Bird & Cronin (US), Compass Health Brands (US), Breg, Inc. (US), Medline Industries (US), Performance Health (US), Romsons Group of Industries (India), Unexo Life Sciences (India), Polar Products (US), Rapid Aid (Canada), Mueller Sports Medicine (US), Pic Solution (US), Bruder Healthcare Company (US), Brownmed Inc. (US), Medichill (Australia), and ThermoTek, Inc. (US).

Q. What are the factors driving the cold pain therapy market growth?

Ans. The major factors driving the growth of the market are the increasing R&D.

Q. What are the key growth strategies of cold pain therapy market players?

Ans. The key growth strategies of cold pain therapy market players are product launch and product approval.

Q. Which region will provide more business opportunities for the cold pain therapy market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the cold pain therapy market during the forecast period.

 

Read More
Single User License

Closed System Transfer Devices Market
June, 2022

The global closed system transfer devices market was valued at USD 914.0 Million in 2021 and it is anticipated to grow at 18.1% CAGR during the forecast period to reach up to USD 4834.1 Million by 2031.

A closed system transfer device or “CSTD” is a drug transfer device, which mechanically restricts the transfer of environmental contamination in the medical system and the escape of hazardous drug or vapor concentrations outside the system. Open versus closed systems are commonly applied in medical devices to maintain the sterility of a fluid pathway. CSTDs work by preventing- uncontrolled inflow and outflow of contaminants and drugs, preserving the quality of the solution to be infused into a patient. These devices ensure the safety of healthcare workers during the usage of hazardous drugs or chemicals. Closed system transfer device designs and models have changed at a rapid rate in recent years, resulting in the development of a number of independent testing methodologies to assess closed system transfer device performance. Currently, manufacturers in the closed system transfer devices market are focusing more on adhering to performance requirements, which largely focus on patient safety and sterile practices.

Global Closed System Transfer Devices Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$914.0 mn
Market Size in 2031$4834.1 mn
Growth Rate (2021-31)18.1%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredClosing Mechanism, Type, Component, End User, and Region
Key CompaniesB. Braun Holding GmbH & Co. KG, Baxter International, Becton, Dickinson and Company, Caragen Ltd, Corvida Medical, Equashield, FIMI Opportunity Funds (Simplivia Healthcare), ICU Medical, JCB Co Ltd. (JMS Co Ltd.), Yukon Medical.
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors such as rising use of CSTDs to combat the harmful effect of cytotoxic and antineoplastic drugs. Antineoplastic drugs are widely used in the treatment of cancer and are considered hazardous drugs. Healthcare workers involved in the preparation, transport, distribution, administration (pre and post-administration), and disposal of these drugs are at extremely high risk. The National Institute for Occupational Safety and Health (NIOSH) recommends the use of CSTDs to eliminate the harmful effects caused by exposure to hazardous substances that escape out of the system during drug preparation and administration. CSTDs act as a barrier and prevents the entry of contaminants prevent the transfer of contaminants from the atmosphere to a sterile environment. Due to these advantages, CSTDs are increasingly being used in healthcare facilities to combat the harmful effects of hazardous drugs.

Chemotherapy, a widely adopted cancer treatment, uses one or more antineoplastic drugs, which destroy abnormal cells in patients. The use of closed system transfer devices (CSTDs) in conjunction with other safety precautions such as gloves, gowns, masks, and vented preparation hoods is an effective way to increase safety when preparing, transporting, administering, and disposing of hazardous drugs. With the increasing incidence of cancer and increasing adoption of chemotherapy treatments, the demand for CSTDs is expected to increase in the upcoming years.

Market Restraints and Challenges

The major factor hindering the market growth is the high cost of implementation of CSTDs and lack of reimbursement. The cost of a closed system transfer device is one of the major constraints limiting its adoption in healthcare facilities. The cost of a typical CSTD primarily depends upon factors like manufacturer, components used, and drug that is to be administered. Moreover, since CSTDs are meant for single-use, the cost per unit is higher than regular syringes. The median price of CSTD ranges between USD8-12 per dose. According to the regulatory guidelines, CSTDs are categorized as IV consumables. Its usage is not mandatory in European and other developing nations. Since the use of these devices is absolutely voluntary in these countries, its reimbursement is unlikely. Hence, the lack of standard guidelines further acts as a hindrance to the adoption of these devices.

Global Closed System Transfer Devices Market Segmentation

The report analyses the global closed system transfer devices market based on closing mechanism, type, component, end user, and region.

Global Closed System Transfer Devices Market by Closing Mechanism

Based on the closing mechanism, it is segmented into the push to lock system, click to lock system, Luer lock system, and color to color alignment system. Color to color alignment system is likely to dominate the market during the forecast period. Owing to its unique structure that prevents leaks, spills, or the escape of vapors and aerosols. These devices equalize the pressure within the system when fluids are withdrawn or injected into vials. Additionally, the low cost of this system, along with its advantages, increased its adoption among pharmacists, oncologists, and nurses.

Global Closed System Transfer Devices Market by Type

Based on type, it is segmented into the membrane to membrane systems, and needleless systems. The membrane to membrane system is anticipated to dominate the market during the forecast period. The key factors such as ease of operation and lower risk of contamination associated with double membrane containment systems are boosting the market growth.

Global Closed System Transfer Devices Market by Component

Based on component, it is segmented into vial access devices, syringe safety devices, bag/line access devices, and accessories. The vial access devices segment is estimated to dominate the market during the forecast period. The key factors such as rising adoption of CSTDs products and vial access device by oncology nurses to transfer hazardous drugs from packaged vials to the infusion bag or the patient.

Global Closed System Transfer Devices Market by End User

Based on end user, it is segmented into hospitals & clinics, oncology centers, and other end users. The hospitals & clinics segment is likely to dominate the market during the forecast period. The large share and high growth of this segment are primarily owing to the strong financial capabilities of hospitals for purchasing high-priced CSTDs, the large cancer patient pool, and the need to comply with regulatory guidelines.

Geographical Analysis of Closed System Transfer Devices Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is likely to dominate the market during the forecast period. The key factors such as easy accessibility to advanced technologies, high awareness about CSTD among oncologists, nurses, and pharmacists, and the presence of many CSTD manufacturing players in the region coupled with high incidences of cancer.

Major Players in Closed System Transfer Devices Market

The key players in the closed system transfer devices market are B. Braun Holding GmbH & Co. KG, Baxter International, Becton, Dickinson and Company, Caragen Ltd, Corvida Medical, Equashield, FIMI Opportunity Funds (Simplivia Healthcare), ICU Medical, JCB Co Ltd. (JMS Co Ltd.), Yukon Medical.

COVID-19 Impact

The outbreak of COVID-19 led to a decrease in the demand for CSTDs during the first two quarters of 2020. Due to the virus containment norms and nationwide lockdowns, there were limited patient footfalls in hospitals, mostly related to COVID-19 and emergency cases. The elective medical procedures are on hold thereby causing a negative shift in the demand for CSTDs. Still, with the decline in the number of active COVID-19 cases coupled with the economic recovery in developed nations, further utilization of these devices may be expected in the near future.

Recent Developments
  • January 2021, Simplivia Healthcare acquired 70% of Novame d, a diagnostic company that develops and manufactures a range of diagnostic kits to meet evolving trends of home care.
  • May 2021, BD expanded its drug delivery devices segment by establishing a high-tech manufacturing facility in Zaragoza, Spain.
  • May 2021, Yukon Medical received US FDA clearance for Arisure closed system transfer device under the ONB product classification.
  • November 2020, Equashield LLC partnered with Syntronic Hospitalar to introduce Equashield’s products in Brazil.
Frequently Asked Questions

Q. How big is the closed system transfer devices market?

Ans. The global closed system transfer devices market size was USD 914.0 Billion in 2021 and is anticipated to reach USD 4834.1 Billion in 2031, growing at a rate of 18.1% from 2022 to 2031.

Q. What is the closed system transfer devices market growth rate?

Ans. The growth rate of the closed system transfer devices market is 18.1% from 2022 to 2031.

Q. Which region holds a major market share for the closed system transfer devices market?

Ans. North America holds a major market share of the closed system transfer devices market in 2021.

Q. Which segment accounted for the largest closed system transfer devices market share?

Ans. By closing mechanism, the color to color alignment system segment accounted for the largest closed system transfer devices market share.

Q. Who are the key players in the closed system transfer devices market?

Ans. The global closed system transfer devices market report includes players such as B. Braun Holding GmbH & Co. KG, Baxter International, Becton, Dickinson and Company, Caragen Ltd, Corvida Medical, Equashield, FIMI Opportunity Funds (Simplivia Healthcare), ICU Medical, JCB Co Ltd. (JMS Co Ltd.), Yukon Medical.

Q. What are the factors driving the closed system transfer devices market growth?

Ans. The major factors driving the growth of the market are the increasing R&D.

Q. What are the key growth strategies of closed system transfer devices market players?

Ans. The key growth strategies of closed system transfer devices market players are product launch and product approval.

Q. Which region will provide more business opportunities for the closed system transfer devices market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the closed system transfer devices market during the forecast period.

Read More
Single User License

Clinical Chemistry Analyzers Market
June, 2022

The global clinical chemistry analyzers market was valued at USD 12.6 billion in 2021 and it is anticipated to grow at 4.2% CAGR during the forecast period to reach up to USD 19.7 billion by 2031.

Clinical chemistry analyzers are used to calculate the concentration of certain electrolytes, metabolites, and drugs in serum, cerebrospinal fluid, and other body fluids among others. It creates an accurate result within the lease period and is planned for extremely advanced technology. It is used to validate health conditions like nutritional status, liver functions, and kidney functions among others. Different types of tests such as lipid profile, liver panel, and a renal panel comprising therapeutic drugs are used to enhance metabolic functions. Rising demand for clinical tests and the increasing prevalence of endocrine diseases are the major factors driving the growth of the market.

Global Clinical Chemistry Analyzers Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$12.6 bn
Market Size in 2031$19.7 bn
Growth Rate (2021-31)4.2%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Test Type, End User, and Region
Key CompaniesF. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor propelling the growth of the market is the rising geriatric population coupled with the increasing prevalence of chronic and lifestyle diseases. The increasing geriatric population in developed and developing regions will positively influence the growth of the clinical chemistry analyzers market. Owing to rapid growth in the elderly population, the prevalence of age-associated diseases like hypertension, diabetes, cardiovascular, liver, and kidney diseases are anticipated to increase significantly. The diagnosis and management of such diseases are responsible for the rising number of prescriptions for tests like basic metabolic panel, lipid profile, and liver & renal panel. The growth in chronic illnesses will increase the demand for tests prescribed for the prevention, diagnosis, and treatment of the same. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for clinical chemistry analyzers during the projection period. These tests are performed by clinical chemistry analyzers; so, it is expected to have a positive impact on this market.

Market Restraints and Challenges

The major factor hindering the growth of the market is the requirement of high capital investment and a shortage of skilled laboratory technicians. The high-volume clinical chemistry analyzers may be affordable only for large hospitals and reference laboratories with high capital budgets. Most small laboratories, physician’s offices, and sole practitioners have no capital budgets and may not be able to afford a large or very large-sized analyzer. So, the high fixed-cost requirements limit the growth of the clinical chemistry analyzers market.

Currently, there is a significant shortage of laboratory technicians in both developed and developing nations. This is primarily attributed to the increasing patient population base, the retirement of elderly technicians, and the rising number of cash-strapped colleges closing their clinical lab programs. So, there is a gap between the supply and demand of pathologists and lab technicians worldwide, therefore expecting to restrain the market growth.

Global Clinical Chemistry Analyzers Market Segmentation

The report analyses the global clinical chemistry analyzers market based on product, test type, end user, and region.

Global Clinical Chemistry Analyzers Market by Product

Based on product, it is segmented into reagents, analyzers, and other products. The reagents segment is likely to dominate the market during the forecast period. The recurrent requirement of reagents in large numbers as compared to analyzers is the primary factor boosting the growth of this segment.

Global Clinical Chemistry Analyzers Market by Test Type

Based on test type, it is segmented into basic metabolic panels, liver panels, renal panels, lipid profiles, thyroid function panels, electrolyte panels, and specialty chemical tests. The basic metabolic panel tests segment accounted for the largest share during the forecast period. This can be attributed to the increasing incidence of diabetes and other lifestyle and chronic diseases and the increasing trend of preventive healthcare.

Global Clinical Chemistry Analyzers Market by End User

Based on end user, it is segmented into hospitals & clinics, diagnostic laboratories, research laboratories & institutes, and others. The hospitals & clinics segment is likely to dominate the market during the forecast period. The key factors such as growing adoption of point of care testing devices coupled with increasing demand for laboratory automation is propelling the market growth.

Geographical Analysis of Global Clinical Chemistry Analyzers Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global clinical chemistry analyzers market. The growth is primarily attributed to the increasing geriatric population coupled with the increasing prevalence of chronic and lifestyle conditions, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.

Major Players in Global Clinical Chemistry Analyzers Market

The key players in the global clinical chemistry analyzers market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).

COVID-19 Impact

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the sales of the companies. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. Conversely, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious diseases has become a pressing medical issue across the globe. Additionally, with the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities.

Recent Development
  • January 2020, Sysmex invested in Astrego Diagnostics for the development of urinalysis solutions.
  • July 2019, Trivitron Healthcare introduced the ‘Nanolab 200,’ a fully automated chemistry analyzer. The new product is an automated benchtop chemistry analyzer with a throughput of approximately 200 tests per hour. The newly launched product, which is integrated with cutting-edge liquid level detection technology, is anticipated to improve efficiency levels in clinical laboratories.
  • December 2018, BIOBASE Group launched BK200 mini auto chemistry analyzer for small laboratories and clinics to meet the needs of its customers.
  • November 2017, Roche Diagnostics acquired Viewics (US) to expand its leading position in the integrated core lab space with business analytics capabilities.
Frequently Asked Questions

Q. How big is the clinical chemistry analyzers market?

Ans. The global clinical chemistry analyzers market size was USD 12.6 Billion in 2021 and is anticipated to reach USD 19.7 Billion in 2031, growing at a rate of 4.2% from 2022 to 2031.

Q. What is the clinical chemistry analyzers market growth rate?

Ans. The growth rate of the clinical chemistry analyzers market is 4.2% from 2022 to 2031.

Q. Which region holds a major market share for the clinical chemistry analyzers market?

Ans. North America holds a major market share of the clinical chemistry analyzers market in 2021.

Q. Which segment accounted for the largest clinical chemistry analyzers market share?

Ans. By product, the reagents segment accounted for the largest clinical chemistry analyzers market share.

Q. Who are the key players in the clinical chemistry analyzers market?

Ans. The global clinical chemistry analyzers market report includes players such as F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).

Q. What are the factors driving the clinical chemistry analyzers market growth?

Ans. The major factors driving the growth of the market are the increasing geriatric populations.

Q. What are the key growth strategies of clinical chemistry analyzers market players?

Ans. The key growth strategies of clinical chemistry analyzers market players are product launch and product approval.

Q. Which region will provide more business opportunities for the clinical chemistry analyzers market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the clinical chemistry analyzers market during the forecast period.

Read More
Single User License

Cardiac Marker Testing Market
June, 2022

The global cardiac marker testing market was valued at USD 3.9 billion in 2021 and it is anticipated to grow at 10.4% CAGR during the forecast period to reach up to USD 10.5 billion by 2031.

Cardiac markers are utilized in the treatment and risk stratification of patients with the suspected coronary acute syndrome (ACS). Troponin I and T, HDCRP, myoglobin, CK-MB, and other cardiac marker tests are among the most common. When the heart is stressed or injured, substances called cardiac markers are released into the blood. Hormones, enzymes, and proteins are examples of these markers. These biomarkers can be helpful to detect a variety of heart disorders, comprising acute coronary syndrome, cardiac ischemia, and conditions involving obstructed blood flow to the heart. Physicians perform several cardiac marker tests over several hours to keep track of the blood sugar increase and determine the severity of a heart attack.

Global Cardiac Marker Testing Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$3.9 bn
Market Size in 2031$10.5 bn
Growth Rate (2021-31)10.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Biomarker Type, Disease, End User, and Region
Key CompaniesRoche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the growth of the market is the growing incidence of cardiovascular diseases. The prevalence of lifestyle diseases such as hypertension, obesity, dyslipidemia, and diabetes, which are major risk factors for CVD, is also on the rise. In 2016, more than 1.9 billion adults globally were overweight; of these, over 600 million people were obese. It is anticipated that ~41% of the world’s population will be overweight or obese by 2030. The association between obesity and the risk of coronary heart disease was published by investigators (Bogers RP, Bemelmans WJ, Hogeveen RT, et al.) by a meta-analysis of 21 long-term studies conducted by them with more than 300,000 participants. It was witnessed that participants who were overweight had a 32% higher risk of developing coronary artery disease (CAD), and those who were obese had an 81% higher risk as compared with participants who were a normal weight.

Market Restraints and Challenges

The major factor hindering the market growth is technical problems related to sample collection and storage. Many epidemiology studies use cardiac biomarkers to investigate different stages of diseases in humans. It requires careful handling and storage of precious biological samples with the goal of obtaining a large amount of information from limited samples and reducing future research costs with the use of banked samples. Sample collection is thus one of the key issues faced by service providers, followed by access to these samples. Similarly, stringent quality control is also required for these samples, and they need to be stored under the right conditions to avoid any damage. Adding to that, different samples are required for risk detection, screening, diagnosis, and monitoring processes. The validity of results from cardiac biomarker studies using archived specimens is dependent on the integrity of specimens and the manner in which they were collected, processed, and stored.

Global Cardiac Marker Testing Market Segmentation

The report analyses global cardiac marker testing market based on product, biomarker type, disease, end user, and region.

Global Cardiac Marker Testing by Product

Based on product, it is segmented into reagents & kits, and instruments. The reagents and kits segment is likely to dominate the market during the forecast period. The growing number of cardiac marker testing procedure, accessibility to a wide range of cardiac biomarker reagents and kits combined with growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the primary factor boosting the market growth during the forecast period.

Global Cardiac Marker Testing Market by Biomarker Type

Based on biomarker type, it is segmented into troponin I and T, CK-MB, Bnp or Nt-Probnp, Myoglobin, Hscrp, and others. Troponin I and T is anticipated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed to high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

Global Cardiac Marker Testing Market by Disease

Based on disease, it is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and ischemia. The myocardial infarction segment is likely to dominate the market during the forecast period. The key factors such as the growing incidence of cardiovascular diseases coupled with the rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases across the globe are boosting the growth of the market.

Global Cardiac Marker Testing Market by End User

 

Based on end user, it is segmented into laboratory testing, academic institutions, and point of care testing facilities. The laboratory testing segment is likely to dominate the market during the forecast period. The key factors such as growing funding from public and private organizations for research on cardiac biomarkers coupled with ongoing clinical trials for the identification of novel cardiac biomarkers are boosting the growth of the market.

Geographical Analysis of Global Cardiac Marker Testing Market

 

Region-wise, it is studied across North America, Europe, Asia Pacific, and the rest of the World. The North America is likely to dominate the market during the forecast period. The increasing incidence of cardiovascular diseases coupled with growing public and private investments, NIH support for the development of novel cardiac biomarkers, and the rising geriatric population is boosting the market growth.

Major Players in Global Cardiac Marker Testing Market

The key players in the global cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), Tosoh Corporation (Japan).

COVID-19 Impact

The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which comprises outpatient clinics, investigations, procedures, and cardiology community services like cardiac rehabilitation.

Recent Developments
  • May 2020, Roche acquired Stratos genomics to further develop DNA.
  • April 2019, Roche diagnostics launched the VITROS high-sensitivity Troponin I assay.
  • May 2019, Abbott launched the next generation smartphone connectable confirm RX, which FDA and CE Mark accept for implantable continuous cardiac monitoring. It is for quick and early diagnosis of remote monitoring heart problems.
Frequently Asked Questions

1. How big is the cardiac marker testing market?

Ans. The global cardiac marker testing market size was USD 3.9 Million in 2021 and is anticipated to reach USD 10.5 Million in 2031, growing at a rate of 10.5% from 2022 to 2031.

2. What is the cardiac marker testing market growth rate?

Ans. The growth rate of the cardiac marker testing market is 10.5% from 2022 to 2031.

3. Which region holds a major market share for the cardiac marker testing market?

Ans. North America holds a major market share of the cardiac marker testing market in 2021.

4. Which segment accounted for the largest cardiac marker testing market share?

Ans. By disease, the myocardial infarction segment accounted for the largest cardiac marker testing market share

5. Who are the key players in the cardiac marker testing market?

Ans. The global cardiac marker testing market report includes players such as Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), Tosoh Corporation (Japan.

6. What are the factors driving the cardiac marker testing market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of cancer.

7. What are the key growth strategies of cardiac marker testing market players?

Ans. The key growth strategies of cardiac marker testing market players are product launch and product approval.

8. Which region will provide more business opportunities for the cardiac marker testing market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the cardiac marker testing market during the forecast period.

Read More
Single User License

Cancer Biomarkers Market
June, 2022

The global cancer biomarkers market size was USD 13.4 billion in 2021 and it is anticipated to reach USD 63.6 billion by 2031, growing at a CAGR of 16.9% from 2022-2031.

Cancer biomarkers are substances or processes that indicate the presence of cancers in the human body, estimated by collecting samples such as stool, tumor tissue, blood, urine, or other tissues or bodily fluids. Biomarkers may be formed by the cancer tissue itself or by other cells in the body in response to cancer. They enhance cancer detection and assist in high-speed noninvasive diagnosis using genomics and proteomics.

Global Cancer Biomarkers Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$13.4 bn
Market Size in 2031$63.6 bn
Growth Rate (2021-31)16.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredBiomarker Type, Cancer Type, Profiling Technologies, Application, and Region
Key CompaniesF. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the growth of the market is rising technological advancements in the development of cancer biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to great extent.

Similarly, the growing preference for personalized medicine is also boosting the growth of the market. Personalized medicine identifies the most beneficial treatment path for individual patients. Cancer biomarkers play a very important role in certain aspects of personalized medicine. Consumables used in cancer biomarker testing enable the identification of these diseases. Cancer biomarker diagnostic products are also used as companion diagnostics for several investigational therapies. So, the field of personalized medicine is likely to offer potential growth opportunities for players operating in the cancer biomarkers market.

Market Restraints and Challenges

The key factor hampering the growth of the global cancer biomarker market is technical issues related to sample collection and storage. The sample collection is one of the key issues for service providers, followed by access to these samples. Stringent quality control of this sample is essential, and they need to be stored under the right conditions to avoid any loss. Additionally, different samples are required for risk detection, screening, diagnosis, and monitoring processes. Likewise, challenges associated with cancer biomarker validation is also hindering the growth of the market. The cancer biomarker validation process comprises evaluation assays or measuring performance characteristics like sensitivity, specificity, and reproducibility. Validation is critical for establishing cancer biomarkers as reliable tool to support development, medical care, and biopharma investment decisions.

Global Cancer Biomarkers Market Segmentation

The report analyses the global cancer biomarkers market based on biomarker type, cancer type, profiling technologies, application, and region.

Global Cancer Biomarkers Market by Biomarker Type

Based on biomarker type, it is segmented into protein biomarkers, genetic biomarkers, and others. The protein biomarker segment is likely to dominate the market during the forecast period. The key factors such as increasing research on cancer biomarkers are propelling the growth of the market.

Global Cancer Biomarkers Market by Cancer Type

Based on cancer type, it is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The breast cancer segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing incidence of cancer across the globe are boosting the growth of the market.

Global Cancer Biomarkers Market by Profiling Technologies

Based on profiling technologies, it is segmented into omics technologies, imaging technologies, immunoassays, bioinformatics, and cytogenetics. The omics technologies are estimated to dominate the market during the forecast period. The key factors such as the increased use of cancer biomarkers for new developments are boosting the growth of this segment.

Global Cancer Biomarkers Market by Application

Based on application, it is segmented into, it is segmented into diagnostics, research & development, prognostics, risk assessments, and others. The diagnostic segment is likely to dominate the market during the forecast period. The factors such as an increase in the application of cancer biomarkers for companion diagnostics will boost the market growth during the forecast period.

Geographical Analysis of Global Cancer Biomarkers Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global cancer biomarkers market. The North American cancer biomarkers market’s growth can be attributed to the correlation between the rising population and increased research activities.

Major Players in Global Cancer Biomarkers Market

The major key players in the cancer biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

COVID-19 Analysis

It was primarily thought novel coronavirus (covid-19, sars-cov-2) was majorly a respiratory disorder, but as larger numbers of patients contracted the virus, it rapidly became clear it had many physiological manifestations. The impact of covid-19 goes well beyond the lungs to impact the cardiovascular system and cause complications in the kidneys, brain, and other organs. Critical patients frequently require care from a multidisciplinary care team. Moreover, COVID patients with comorbidities were more likely to have severe symptoms requiring hospitalization. Yet, patients with pre-existing cardiovascular diseases suffer the highest mortality rate of all COVID patients.

The implications of decreased testing are of great concern for many stakeholders, comprising physicians, hospitals, laboratories, pharmaceutical companies, and, most probably, patients. Diagnosis and cancer biomarker testing is the earliest indicators of treatment, which may comprise new targeted therapies with the potential to improve patient results; they should not be delayed. Routine screening for breast, ovarian and colorectal cancer also needs to be done timely as they constitute effective preventive and early detection measures. The pandemic has significantly and negatively altered how cancer patients are being diagnosed and treated in the upcoming years.

Recent Developments
  • February 2022, Onco DNA introduced the Onco Deep Solid Tumor Biomarker Test Kit. The Onco Deep kit, which comprises Twist Bioscience’s enrichment and library preparation solutions, will give labs a complete and reliable solution for performing comprehensive NGS analysis of tumor samples.
  • April 2021, F. Hoffmann-La Roche Ltd., launched Elecsys Anti-p53 immunoassay to assist in the diagnosis of various cancer types.
  • December 2020, Thermo Fisher Scientific (US) received FDA approval for NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
  • April 2020, Qiagen N.V. launched the therascreen BRAF test as a companion diagnostic to a BRAFTOVI-based regimen in metastatic colorectal cancer.
  • May 2019, Biotech Support Group (BSG) and Leiden University Medical Center (LUMC) have established a research partnership to identify stromal conditioning biomarkers in Cancer.
Frequently Asked Questions

Q. How big is the cancer biomarkers market?

Ans. The global cancer biomarkers market size was USD 13.4 Million in 2021 and is anticipated to reach USD 63.6 Million in 2031, growing at a rate of 16.9% from 2022 to 2031.

Q. What is the cancer biomarkers market growth rate?

Ans. The growth rate of the cancer biomarkers market is 16.9% from 2022 to 2031.

Q. Which region holds a major market share for the cancer biomarkers market?

Ans. North America holds a major market share of the cancer biomarkers market in 2021.

Q. Which segment accounted for the largest cancer biomarkers market share?

Ans. By application, the diagnostic segment accounted for the largest cancer biomarkers market share

Q. Who are the key players in the breath analyzer market?

Ans. The global cancer biomarkers market report includes players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).

Q. What are the factors driving the cancer biomarkers market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of cancer.

Q. What are the key growth strategies of cancer biomarkers market players?

Ans. The key growth strategies of cancer biomarkers market players are product launch and product approval.

Q. Which region will provide more business opportunities for the cancer biomarkers market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for cancer biomarkers market during the forecast period.

Read More
Single User License

Breath Analyzer Market
June, 2022

The global breath analyzers market size was USD 534.0 million in 2021 and it is anticipated to reach USD 2594.2 million in 2031, growing at a CAGR of 17.1% from 2022-2031.

The Breath Analyzer is a device used to track the Blood Alcohol Content (BAC) in an individual, through a breath sample. The test performed depends upon the relationship between alcohol in the blood or in the breath flowing through the lungs. The rising trend of extreme alcohol consumption resulting in road accidents; has raised the usage of breathalyzer devices. Encouraging government initiatives are also boosting the market growth. Breathalyzer devices are also gaining importance owing to the increasing demand at the workplace for effective BAC (blood alcohol content) levels and their non-invasive nature which is increasing the demand for breath analyzer devices. It is a primary tool for monitoring drugs, alcohol, tuberculosis, asthma, and other diseases hence; it is anticipated that the demand for this system should constantly rise.

Global Breath Analyzers Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$534.0 mn
Market Size in 2031$2594.2 mn
Growth Rate (2021-31)17.1%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredTechnology, Application, End User, and Region
Key CompaniesDrägerwerk AG & Co. KGaA (Germany), MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors boosting the growth of the market are rising alcohol abuse and drug abuse. In 2018, about 10,511 people in the US died because of drunk driving. Excessive alcohol consumption leads to a high risk of developing more than 200 diseases, comprising liver cirrhosis and some cancers. In the US almost 30 people die every day owing to driving under the influence (DUI). Additionally, high blood alcohol content was observed in~20% of fatally injured drivers in accidents in developed countries. The growing number of road accidents caused by drunk driving and drug abuse has increased the demand for breath analyzers, as these devices assist in monitoring the presence of different compounds and measuring the blood alcohol content in a breath sample.

Similarly, technological advancements are also boosting the growth of the market. The breath analyzers market is technology-driven and is projected to grow at a significant rate in the upcoming years. Due to the lucrative potential of the market, a number of players are focusing on developing novel technologies and are continuously introducing accurate and easy-to-use breath analyzers. For instance, in August 2019, Y Combinator, an investment company, invested in SannTek Labs to work on a new kind of breathalyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person has consumed in the past 3 to 4 hours.

Market Restraints and Challenges

The major factor hampering the growth of the market is the accuracy concern of the breath analyzers. At times, breath analyzers provide inaccurate results failing to distinguish alcohol from any other chemical compound that includes a methyl group structure. Some alcohol testing machines identify not only ethyl alcohol (found in alcoholic drinks) but also any compound with a related molecular structure. Additionally, lip gloss, mouthwash, dentures, paint, glue, thinners, cleaning solvents, the foam used for hand hygiene, cigarettes, and even inhalers used for asthma can also hinder the test results of breath analyzers.

Global Breath Analyzers Market Segmentation

The report analyses the global breath analyzers market based on technology, application, end user, and region.

Global Breath Analyzers Market by Technology

Based on technology, it is segmented into the fuel cell, semiconductor oxide sensor, and others. The fuel cells segment is likely to dominate the market during the forecast period. Fuel cell breath analyzers offer an extremely high level of accuracy, sensitivity, and reliability. They are specifically tuned to detect alcohol and do not require multiple sensors. These analyzers are considered the gold standard of handheld alcohol testers for both personal and professional use.

Global Breath Analyzers Market by Application

Based on application, it is segmented into alcohol detection, drug abuse detection, and medical applications. The alcohol detection segment is likely to dominate the market during the forecast period. The key factors such as stringent government regulations for driving under influence (DUI) is boosting the growth of the market.

Global Breath Analyzers Market by End User

Based on end user, it is segmented into law enforcement agencies, enterprises, and individuals. The law enforcement agencies segment accounted for the largest market share in 2021. This segment is also projected to register the highest CAGR during the projection period. The growth of this segment is primarily drivenby stringentsafety laws against DUI and the rising scale of screening and evidential testing are driving the adoption of breath analyzers in law enforcement.

Geographical Analysis of Breath Analyzers Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North America dominated the global breath analyzers market. The Asia Pacific market is anticipated to register the highest CAGR during the projection period. The major factor boosting the growth of the market is rising alcohol consumption of alcohol coupled with increasing research on the medical applications of breath analyzers, and the development of advanced breath analyzers.

Major Players of the Global Breath Analyzers Market

The global breath analyzer market report comprises players such as Drägerwerk AG & Co. KGaA (Germany), MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany), Lion Laboratories Ltd. (UK), Pas Systems International (US), Guth Laboratories, Inc (US), Alcolizer Technology (Australia), Alcopro, Inc (US), Andatech Private Ltd (Australia), Alere (US), C4 development (China), Advanced Safety Devices (US), and Bedfont Scientific Limited (UK).

COVID-19 Analysis

The COVID-19 outbreak has upended many lives and businesses on an unprecedented scale. The pandemic has caused significant hindrances to businesses and economic activities across the globe. Various governments across the globe have provided guidelines to postpone or delay non-essential medical and surgical procedures to reduce the strain on the healthcare system and reduce disease transmission. Restrictions and lockdowns were also imposed in the areas of travel, business operations, public gatherings, gaming or gambling venues, casinos, health clubs, fitness/wellness centers, and shelter-in-place orders, all of which have further impacted market growth.

Recent Developments
  • July 2020, Lifeloc Technologies launched LT7 and LX0 breath analyzers. These are US DOT/NHTSA approved breath alcohol testers for law enforcement and workplace markets designed to be user-friendly.
  • August 2019, Y Combinator, an investment company, invested in Sann Tek Labs to work on a new kind of breath analyzer. This breathalyzer is designed to detect blood alcohol levels as well as the type of cannabis a person consumed in the past 3 to 4 hours.
  • August 2019, Abbott and Intoximeters signed an agreement for intoximeters to market Abbott’s So Toxa Mobile Test System along with Intoximeter’s Alco-Sensor brand breath alcohol-testing products.
Frequently Asked Questions

Q. How big is the breath analyzers market?

Ans. The global breath analyzers market size was USD 534.0 Million in 2021 and is anticipated to reach USD 2594.2 Million in 2031, growing at a rate of 17.1% from 2022 to 2031.

Q. What is the breath analyzers market growth rate?

Ans. The growth rate of the breath analyzers market is 17.1% from 2022 to 2031.

Q. Which region holds a major market share for the breath analyzers market?

Ans. North America holds a major market share of the breath analyzers market in 2021.

Q. Which segment accounted for the largest breath analyzers market share?

Ans. By application, the alcohol detection segment accounted for the largest breath analyzers market share

Q. Who are the key players in the breath analyzer market?

Ans. The global breath analyzers market report includes players such as Drägerwerk AG & Co. KGaA (Germany), MPD, Inc (US), Lifeloc Technologies (US), BACtrack, Inc. (US), Quest Products, Inc. (US), Akers Biosciences, Inc. (US), Intoximeter, Inc. (US), AK GlobalTech Corporation (US), Alcohol Countermeasure Systems Corporation (Canada), EnviteC-Wismar GmbH (Germany), Lion Laboratories Ltd. (UK), Pas Systems International (US), Guth Laboratories, Inc (US), Alcolizer Technology (Australia), Alcopro, Inc (US), Andatech Private Ltd (Australia), Alere (US), C4 development (China), Advanced Safety Devices (US), and Bedfont Scientific Limited (UK).

Q. What are the factors driving the breath analyzers market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of alcohol and drug abuse.

Q. What are the key growth strategies of breath analyzers market players?

Ans. The key growth strategies of breath analyzers market players are product launch and product approval.

Q. Which region will provide more business opportunities for the breath analyzers market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for breath analyzers market during the forecast period.

 

Read More
Single User License

Clinical Trial Imaging Market
June, 2022

The global clinical trial imaging market was valued at USD 1.2 billion in 2021 and it is anticipated to grow at 5.9% CAGR during the forecast period to reach up to USD 2.1 billion by 2031.

Clinical Trial Imaging comprises the use of imaging modalities, analysis services, and software to effectively determine the efficacy of novel medications prior to commercial release. Clinical Imaging techniques are increasingly used in oncology drug clinical trials to provide evidence for the drug’s effectiveness and safety. The imaging systems commonly used in clinical trials comprise Positron Emission Tomography (PET), Optical Coherence Tomography (OCT), Magnetic Resonance Imaging (MRI), and Ultrasound. The growth in the number of cancer diagnoses and deaths worldwide is estimated to drive the market during the projection period. However, the stringent government regulations in the sector are projected to restrict growth opportunities for the Clinical Trial Imaging Industry.

Global Clinical Trial Imaging Market Scope and Report Structure
Report Attribute Details
Market Size in 2021$1.2 bn
Market Size in 2031$2.1 bn
Growth Rate (2021-31)5.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct & Service, Modality, Therapeutic Area, End User, and Region
Key CompaniesICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor such as an increase in R&D spending is an increase in R&D spending. Pharmaceutical and biotechnology companies invest heavily in research to develop breakthrough molecules. Growth in the R&D expenditure by pharmaceutical & biotechnology companies and governments combined with the increasing focus on life science projects to develop new therapeutic & diagnostic products is estimated to boost the clinical trial imaging market. Likewise, developing countries such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the clinical trial imaging market, mainly owing to the growing R&D funding in these countries. These developing markets also have a strong trend of commercialization of life science research. With significant developments in life sciences research, these economies are anticipated to offer high growth opportunities in the clinical trial imaging market. Moreover, Asian markets, especially China and India, have many CROs that offer drug discovery services to pharmaceutical and biotechnology companies. With the significant increase in R&D funding and CROs operating in emerging countries, the demand for clinical trial imaging is anticipated to boost in these countries in the upcoming years.

Market Restraints and Challenges

The major factor hindering the market growth is the high cost of the clinical trial. Any research related to the advancements in healthcare comprise clinical trials. Clinical trials are an essential part of documenting the effectiveness of innovations, whether for the therapy/drug, medical device, diagnosis, or academic research. While laboratory experiments attempt to stimulate the conditions of the human body, validating the efficacy and safety of drugs in the population of interest remains a necessary step. However, conducting a clinical trial to document the effect of a drug/therapy and monitor its side-effects is a very expensive process.

Global Clinical Trial Imaging Market Segmentation

The report analyses the global clinical trial imaging market based on product & service, modality, therapeutic area, end user, and region.

Global Clinical Trial Imaging Market by Product & Service

Based on product & services, it is segmented into service and software. The service segment accounted for the largest share of the clinical trial imaging market in 2021, mainly owing to the increase in R&D spending and growth in the pharmaceutical and biotechnology industries.

Global Clinical Trial Imaging Market by Modality

Based on modality, it is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, and echocardiography. The computed tomography segment accounted for the largest share. Factors such as the rising number of CROs, increasing R&D spending, and growth in pharmaceutical & biotechnology industries drive this market.

Global Clinical Trial Imaging Market by Therapeutic Area

Based on the therapeutic area, it is segmented into oncology, infectious disease, neurology, CVS, endocrinology, and immunological disorder. The oncology segment is likely to dominate the market during the forecast period. Factors such as rising R&D spending and growth in pharmaceutical & biotechnology industries are driving the market growth.

Global Clinical Trial Imaging Market by End User

Based on the end user, it is segmented into pharmaceutical companies, biotechnology companies, medical device manufacturers, contract research organizations, and academic & government research institutes. The pharmaceutical companies segment accounted for the largest share in the market. The growth in the pharmaceutical & biotechnology companies coupled with an increasing number of CROs and an increase in R&D spending is boosting the growth of the segment.

Geographical Analysis of Clinical Trial Imaging Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the market. The increase in R&D spending coupled with an increase in the number of CROs and growth in the pharmaceutical and biotechnology industries.

Major Players in Global Clinical Trial Imaging Market

The key players in the global clinical trial imaging market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace Klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US).

COVID-19 Impact

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the globe. The COVID-19 pandemic has significantly affected the clinical trial imaging market; unfavorable changes in regulations and guidelines, the closing of manufacturing facilities owing to lockdowns, disruptions in supply chains, and recruitment challenges for clinical trials have severely affected the market growth. Adding to that, limited operations in most industries, inadequate funding for research and academic institutes, and challenges in providing essential/post-sales services due to lockdowns have reduced the supply of clinical trial imaging products to emend-users. Moreover, this is a service-intensive market; providing services became difficult owing to restrictions implemented to control the spread of COVID-19. As the pandemic resulted in the temporary closure of several institutes across the world, many ongoing trials were paused owing to the closure of research institutes.

Despite the challenging situation, industries are slowly recovering from the impact, and supply and distribution channels have also resumed. While the number of trials for diseases like HIV and tuberculosis fell, attention was diverted toward COVID-19 diagnostics and therapeutics, which raised the need for clinical trial imaging.

Recent Developments
  • May 2021, IXICO Plc signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.
  • February 2021, ICON Plc acquired PRA Health Science to strengthen its global healthcare intelligence and clinical research business.
  • February 2021, Resonance Health Ltd received CE mark clearance for Hepa Fat AI software for commercialization in the European market.
  • January 2021, Bioclinica announced the release of Image Redact AI. Bioclinica is an integrated solutions provider of clinical life science and technology expertise.
  • January 2021, Bioclinica acquired Silicon Valley-based Saliency. Bioclinica will integrate the company’s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. The integration will dramatically accelerate image QC and interpretation, enabling the rapid development of digital diagnostics and digital therapeutics.
Frequently Asked Questions

1. How big is the clinical trial imaging market?

Ans. The global clinical trial imaging market size was USD 1.2 Billion in 2021 and is anticipated to reach USD 2.1 Billion in 2031, growing at a rate of 5.9% from 2022 to 2031.

2. What is the clinical trial imaging market growth rate?

Ans. The growth rate of the clinical trial imaging market is 5.9% from 2022 to 2031.

3. Which region holds a major market share for the clinical trial imaging market?

Ans. North America holds a major market share of the clinical trial imaging market in 2021.

4. Which segment accounted for the largest clinical trial imaging market share?

Ans. By product & services, the services segment accounted for the largest clinical trial imaging market share.

5. Who are the key players in the clinical trial imaging market?

Ans. The global clinical trial imaging market report includes players such as ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace Klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US).

6. What are the factors driving the clinical trial imaging market growth?

Ans. The major factors driving the growth of the market are the increasing R&D.

7. What are the key growth strategies of clinical trial imaging market players?

Ans. The key growth strategies of clinical trial imaging market players are product launch and product approval.

8. Which region will provide more business opportunities for the clinical trial imaging market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the clinical trial imaging market during the forecast period.

Read More
Single User License

Capnography Equipment Market
June, 2022

The global capnography equipment market was valued at 344.0 USD Million and it is anticipated to reach USD 530.3 Million by 2031, growing at a constant rate of 4.4% from 2022-2031.

Capnography equipment is conventionally used for cardiology surgeries for patients under deep sedation and anesthesia. Still, with the increasing number of target patients for critical applications such as trauma and emergency cases, the demand for portable/point-of-care capnography equipment is expected to increase. In line with this changing market trend, key market players are primarily focusing on developing portable/point-of-care or handheld capnography equipment that can be used for such applications that require easy device mobility and patient access.

Global Capnography Equipment Market Scope and Structure
Report Attribute Details
Market Size in 2021$344 mn
Market Size in 2031$530.3 mn
Growth Rate (2021-31)4.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct Type, Technology, Application, End User, and Region
Key CompaniesZOLL Medical (Asahi Kasei) (Japan), Becton, Dickinson, and Company (US), Drägerwerk AG & Co. KGaA (Germany), Edan Instruments, Inc. (China), GE Healthcare (US), Hamilton Medical (Switzerland), Welch Allyn (a Hill-Rom company) (US), Koninklijke Philips N.V. (Netherlands), Masimo Corporation (US), Medtronic plc (Ireland)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors such as the development of portable/POC capnography devices. In the initial stages, healthcare professionals can identify potential breathing complications (like airway obstruction, hyperventilation, hypoventilation, or apnea) through ventilation monitoring or capnograph evaluation of target subjects. Real-time measurement of various respiratory parameters helps healthcare professionals decide on patient treatment options and enables timely intervention at the onset of an adverse respiratory event.

Market Restraints and Challenges

The major factor hindering the market growth is the stringent and ambiguous regulatory process for the approval of capnography equipment. Stringent (primarily in the US) and ambiguous regulatory guidelines are restraining the growth of the capnography medical devices market. In the US, it takes around three to seven years to prove the medical safety of any new device. As per the law, even a new size of a previously approved device needs to go through the entire process before commercialization. If a customized product/device is manufactured, the company must go through a long process in which every single part of the device has to be tested and approved separately. Simple capnography equipment receives FDA approval, but complex devices that need to comply with many FDA requirements are a hurdle for the convenience of capnography equipment on a large scale. There are also state legal requirements and manufacturing regulations to pose obstacles to the capnography equipment market.

Global Capnography Equipment Market Segmentation

The report analyses the global capnography equipment market based on product type, technology, application, end user, and region.

Global Capnography Equipment Market by Product Type

Based on product type, it is segmented into capnometers and capnography accessories & disposables. The capnometers segment is likely to dominate the market during the forecast period. The rising adoption of capnography equipment, recommendations for its use in patient monitoring, medical reimbursements for capnography equipment across developed countries, and the rising number of surgical procedures are boosting the growth of the market.

Global Capnography Equipment Market by Technology

Based on technology, it is segmented into the mainstream, Sidestream, and Microstream. The mainstream capnography segment is estimated to dominate the market during the forecast period. The advantages associated with mainstream capnography, like the ease of use and the ability to monitor breathing in intubated patients precisely, are likely to boost the growth of this market.

Global Capnography Equipment Market by Application

Based on application, it is segmented into cardiac surgeries, trauma & emergency care, respiratory monitoring, and others. The cardiac surgery segment is anticipated to dominate the market during the forecast period. The large share of this segment is attributed to the increasing regulatory guidelines recommending capnography for cardiac surgeries coupled with the rising number of cardiopulmonary surgeries performed across the globe.

Global Capnography Equipment Market by End User

Based on end user, it is segmented into hospitals, ambulatory surgery centers & home care, and others. Hospitals dominate the capnography equipment market during the forecast period. Factors such as evolving guidelines related to the use of capnography and the rising incidence of chronic disorders are likely to boost the demand for capnography equipment in hospital settings in the upcoming years.

Geographical Analysis of Global Capnography Equipment Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the market during the forecast period. This can be primarily attributed to the increase in government funding for the establishment of capnography equipment stations, stringent regulations which support the greater adoption of pollution monitoring technologies, and technological advancements in the field of environmental sensors.

Major Players in Global Capnography Equipment Market

The key players comprised in the global capnography equipment market are ZOLL Medical (Asahi Kasei) (Japan), Becton, Dickinson, and Company (US), Drägerwerk AG & Co. KGaA (Germany), Edan Instruments, Inc. (China), GE Healthcare (US), Hamilton Medical (Switzerland), Welch Allyn (a Hill-Rom company) (US), Koninklijke Philips N.V. (Netherlands), Masimo Corporation (US), Medtronic plc (Ireland), Mindray Medical (US), Nihon Kohden (Japan), Nonin Medical Inc.(US), Schiller (Switzerland) and Smiths Medical (UK), Avante (US), Bionics (South Korea), BPL Medical Technologies (India), Burtons Medical Equipment, Ltd. (UK), Criticare Technologies, Inc. (US), Diamedica (UK), Infinium Medical (US), SunMed (US), Nidek Medical India (India), ResMed Inc. (US), RMS (India), Shenzhen Comen Medical Instruments Co., Ltd. (China), SLE Ltd. (UK), UTAS Co. (Ukraine), and Zoe Medical (US).

COVID-19 Analysis

Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting the public and hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the world. Many hospitals have implemented various isolation approaches to minimize the spread of the infection. The demand for capnometers and supporting capnography accessories saw substantial increases. While the shortage of medical products became a serious issue, it also led to increased demand; hence production rose almost tenfold.

Recent Developments
  • December 2021, ZOLL Medical Corporation, an Asahi Kasei Company, closed its acquisition of Itamar Medical Ltd., an Israeli medical device manufacturer. Itamar Medical will operate as a business division within ZOLL.
  • May 2020, Masimo and Philips signed a licensing agreement bringing Masimo Nomo Line Capnography and O3 Regional Oximetry to select Philips’s patient monitors. Philips will integrate additional Masimo measurement technologies into select Intelli Vue MX-series multi-parameter monitors to help clinicians assess cerebral oximetry and ventilation status.
  • April 2021, Masimo Corporation announced the U.S. FDA approval for Radius PCG. It is a portable real-time capnograph with wireless Bluetooth connectivity which provides seamless, tetherless mainstream capnography for patients of all ages. This approval helped the company to gain a competitive edge and strengthen its industrial position.
  • December 2019, Masimo and Drager expanded their Licensing Agreement to comprise Masimo brain monitoring and capnography technologies. Dragger added Masimo nomoline Capnography measurements to its suite of advanced measurement parameters for ORs and critical care.
Frequently Asked Questions

Q. How big is the capnography equipment market?

Ans. The global capnography equipment market size was USD 344 Million in 2021 and is anticipated to reach USD 530.3 Million in 2031, growing at a rate of 4.4% from 2022 to 2031.

Q. What is the capnography equipment market growth rate?

Ans. The growth rate of the capnography equipment market is 4.4% from 2022 to 2031.

Q. Which region holds a major market share for the capnography equipment market?

Ans. North America holds a major market share of the capnography equipment market in 2021.

Q. Which segment accounted for the largest capnography equipment market share?

Ans. By application, the cardiac surgery segment accounted for the largest capnography equipment market share

Q. Who are the key players in the capnography equipment market?

Ans. The global capnography equipment market report includes players such as ZOLL Medical (Asahi Kasei) (Japan), Becton, Dickinson, and Company (US), Drägerwerk AG & Co. KGaA (Germany), Edan Instruments, Inc. (China), GE Healthcare (US), Hamilton Medical (Switzerland), Welch Allyn (a Hill-Rom company) (US), Koninklijke Philips N.V. (Netherlands), Masimo Corporation (US), Medtronic plc (Ireland), Mindray Medical (US), Nihon Kohden (Japan), Nonin Medical Inc.(US), Schiller (Switzerland) and Smiths Medical (UK), Avante (US), Bionics (South Korea), BPL Medical Technologies (India), Burtons Medical Equipment, Ltd. (UK), Criticare Technologies, Inc. (US), Diamedica (UK), Infinium Medical (US), SunMed (US), Nidek Medical India (India), ResMed Inc. (US), RMS (India), Shenzhen Comen Medical Instruments Co., Ltd. (China), SLE Ltd. (UK), UTAS Co. (Ukraine), and Zoe Medical (US).

Q. What are the factors driving the capnography equipment market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of cancer.

Q. What are the key growth strategies of capnography equipment market players?

Ans. The key growth strategies of capnography equipment market players are product launch and product approval.

Q. Which region will provide more business opportunities for the capnography equipment market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the capnography equipment market during the forecast period.

Read More
Single User License

Cancer Diagnostics Market
June, 2022

The global cancer diagnostics market size was USD 18.2 billion in 2021 and it is estimated to reach USD 43.7 billion by 2031, growing at a rate of 9.2% from 2022-2031.

Cancer diagnostics is a method of identifying different diagnostics, proteins, and some signs that leads to the identification of the presence of a cancerous tumor. Efficient diagnostic testing is used to validate or rule out the existence of illness, monitor the progression of the disease, and schedule & review treatment outcomes. Diagnostic procedures for cancer may comprise imaging, tumor biopsy, laboratory tests (comprises tests for tumor diagnostics), endoscopic examination, surgery, or genetic testing.

Report Coverage
Report Attribute Details
Market Size in 2021$18.2 bn
Market Size in 2031$43.7 bn
Growth Rate (2021-31)9.2%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Technology, Application, End User, and Region
Key CompaniesGE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the growth of the market is the growth in the number of private diagnostic centers. The number of private diagnostic centers is increasing across the world as there is a rising demand for diagnostic imaging procedures and a growing burden on public hospitals owing to the limited number of imaging modalities at their disposal.

Market Restraints and Challenges

The primary factor challenging the market growth is the increasing adoption of refurbished diagnostic imaging systems. Many hospitals in developing countries cannot invest in diagnostic imaging equipment due to their higher cost, poor reimbursement rates, and budgetary constraints. However, owing to the high demand for diagnostic imaging procedures in these nations, hospitals that cannot afford to invest in new imaging systems prefer to go for refurbished ones. Refurbished systems are priced lower than new systems and are approximately in the range of 40% to 60% of the original price of the equipment.

Owing to this, many market leaders are now supporting refurbished devices through various programs. For instance, Siemens’ Medical Proven Excellence Program, GE Healthcare’s Gold Seal Program, and Philips’ Diamond Select Program are some noteworthy global refurbishing programs that promote the utilization of refurbished diagnostic imaging systems.

Global Cancer Diagnostics Market Segmentation

The report analyses the cancer diagnostic market based on product, technology, application, end user, and region.

Global Cancer Diagnostics Market by Product

Based on product, it is segmented into consumables and instruments. The consumables segment is likely to dominate the market during the forecast period. The repeated purchase coupled with high consumption, and the high prevalence of diseases are the major factor boosting the growth of this segment.

Global Cancer Diagnostics Market by Technology

By technology, it is segmented into IVD testing, imaging, and biopsy technique. The IVD testing segment is likely to dominate the market in 2021. The key factors such as increasing incidences of cancers are boosting the growth of the market.

Global Cancer Diagnostics Market by Application

Based on application, it is segmented into breast cancer, lung cancer, colorectal cancer, melanoma, and others. The breast cancer segment is likely to continue its dominance during the forecast period. The key factors such as the rising prevalence of breast cancer are boosting the market growth.

Global Cancer Diagnostics Market by End User

Based on the end user, it is segmented into hospitals and diagnostic laboratories. The hospital segment is likely to acquire a major market share during the forecast period. The increasing number of patients visiting hospitals, the rising number of in-house diagnostic procedures performed in hospitals coupled with growing awareness regarding early diagnosis are the major factor boosting the growth of the market.

Geographical Analysis of Global Cancer Diagnostics Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the cancer diagnostics market in 2021. The large share of North America can be attributed to factors such as the rising incidence of cancer coupled with technological advancements.

Major Players in Global Cancer Diagnostics Market

The key players analyzed in the global cancer diagnostics market are GE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US), Siemens Healthineers AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Cancer Diagnostics Inc. (US), Vela Diagnostics (Singapore), Roche Diagnostics (Switzerland), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (US), Bio SB (US), Biocartis NV (Belgium), Exact Science (US).

COVID-19 Analysis

With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the COVID-19. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide being affected by the COVID-19 pandemic.

Recent Developments
  • November 2020, GE Healthcare entered into a partnership with Genesis Care to improve patient outcomes for the two biggest health burdens across the globe, cancer and heart diseases. GE Healthcare will provide CT, MRI, PET/CT, digital mammography, and ultrasound equipment to Genesis Care’s 440+ cancer and cardiovascular disease treatment centers across Australia, the US, the UK, and Spain.
  • January 2020, Roche Diagnostics entered into a partnership with Illumina to provide broad access to clinical oncology next-generation sequencing.
Frequently Asked Questions

Q. How big is the cancer diagnostics market?

Ans. The global cancer diagnostics market size was USD 18.2 Billion in 2021 and is anticipated to reach USD 43.7 Billion in 2031, growing at a rate of 9.2% from 2022 to 2031.

Q. What is the cancer diagnostics market growth rate?

Ans. The growth rate of the cancer diagnostics market is XX% from 2022 to 2031.

Q. Which region holds a major market share for the cancer diagnostics market?

Ans. North America holds a major market share of the cancer diagnostics market in 2021.

Q. Which segment accounted for the largest cancer diagnostics market share?

Ans. By application, the breast cancer segment accounted for the largest cancer diagnostics market share

Q. Who are the key players in the cancer diagnostics market?

Ans. The global cancer diagnostics market report includes players such as GE Healthcare (US), Abbott Laboratories (US), Hologic Inc. (US), Agilent Technologies Inc.(US), Roche Diagnostics (Switzerland), FUJIFILM Corporation (Japan), Danaher Corporation (US), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (US), Siemens Healthineers AG (Germany), BD (US), bioMérieux SA (France), Bio-Rad Laboratories (US), Cancer Diagnostics Inc. (US), Vela Diagnostics (Singapore), Roche Diagnostics (Switzerland), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (US), Bio SB (US), Biocartis NV (Belgium), Exact Science (US).

Q. What are the factors driving the cancer diagnostics market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of cancer.

Q. What are the key growth strategies of cancer diagnostics market players?

Ans. The key growth strategies of cancer diagnostics market players are product launch and product approval.

Q. Which region will provide more business opportunities for the cancer diagnostics market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the cancer diagnostics market during the forecast period.

Read More
Single User License

Breast Reconstruction Market
June, 2022

The global breast reconstruction market size was USD 577 million in 2021 and it is anticipated to reach USD 748.1 million in 2031, growing at a CAGR of 2.6% from 2022-2031.

Breast reconstruction is an important facet of breast cancer management. It has a less cosmetic result. Breast reconstruction provides social, psychological, emotional and functional improvements, counting improved self-esteem, psychological health and body image.

Report Coverage
Report Attribute Details
Market Size in 2021$577 mn
Market Size in 2031$748.1 mn
Growth Rate (2021-31)2.6%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Procedure, Type, End User, and Region
Key CompaniesMentor Worldwide LLC (Johnson & Johnson) (US), Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), and Silimed (Brazil)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The major factor boosting the growth of the market is an increasing awareness about breast reconstruction treatment. A number of patients choose breast reconstruction surgery after mastectomy. This can be primarily attributed to the growing concerns and increasing awareness of the safety and efficacy of reconstructive surgeries. This trend can be observed in both developed and emerging countries which are experiencing improvements in the standard of living.

The growth in awareness can be credited to initiatives taken by market players and stakeholders as well as independent bodies like the American Society of Plastic Surgeons (ASPS). ASPS, along with the Plastic Surgery Foundation, organized the Breast Reconstruction Awareness campaign to engage and educate women on reconstruction post breast cancer diagnosis. The primary target of the campaign was to educate women, family members, and the media that the breast cancer loop remains open until a woman is informed of her breast reconstruction options. Other primary events include the Association of Breast Surgery Conference 2020 in England and the 36th Annual Breast Surgery Symposium held in Georgia, US. In 2011, Canada launched the first BRA Day (Breast Reconstruction Awareness Day). This year, the American Society of Plastic Surgeons and The Plastic Surgery Foundation has joined forces with the Canadians to initiate BRA Day USA. On February 17, 2022, Tata Memorial Center organized a conference – Reconstruction and Cancer Care: Enhancing Quality Living with and Beyond Cancer to create awareness regarding breast reconstruction.

Market Restraints & Challenges

The major factor hindering the growth of the market is alternative non-surgical methods. After mastectomy, some women prefer breast reconstruction surgery. Others do not choose it due to a lack of awareness or other health issues such as obesity, skinniness, or change in blood flow dynamics. These women can choose alternatives to breast reconstruction, like custom breast prosthetics and going flat. Custom breast prosthetics can replicate the woman’s exact shape and create symmetry with the intact breast for single-mastectomy patients. These prosthetics are much cheaper than the breast reconstruction process and are available in the range of under USD 100 to USD 500 for high-quality products. The availability of alternatives, mainly non-surgical methods, is a key restraint to the breast reconstruction market.

Global Breast Reconstruction Market Segmentation

The report analyses the breast reconstruction market based on product, procedure, type, end user, and regions.

Global Breast Reconstruction Market by Product

On the basis of the product, it is segmented into breast implants, tissue expanders, and an acellular dermal matrix. The breast implants segment is likely to dominate the market during the forecast period. The growth of the segment is attributed to the increasing incidences of breast cancer and the rising number of breast reconstruction procedures.

Global Breast Reconstruction Market by Procedure

On the basis of procedure, it is segmented into immediate, delayed, and revision. The immediate segment is likely to dominate the market during the forecast period. The key factors boosting the growth of the market are the increasing number of breast reconstruction procedures combined with an increasing number of breast cancer patients.

Global Breast Reconstruction Market by Type

By type, it is segmented into unilateral, and bilateral. The unilateral segment is likely to dominate the market during the forecast period. The key factors propelling the growth of the market are rapid technological advancements coupled with the high growth opportunities in emerging markets and the rising development of 3D-printed implants.

Global Breast Reconstruction Market by End User

By end user, it is segmented into hospitals, cosmetology clinics and ambulatory surgical centers. The hospital segment is likely to dominate the market during the forecast period. The development and adoption of advanced technologies for breast reconstruction are likely to drive the breast reconstruction market during the projection period.

Geographical Analysis of Global Breast Reconstruction Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to dominate in terms of breast reconstruction market share, due to rising awareness of breast cancer in the region. For instance, in November 2018, a breast reconstruction awareness program was conducted in the Windsor Regional Hospital, Canada, with the special purpose to help and educate local women regarding breast cancer and breast reconstruction.

Major Players of the Global Breast Reconstruction Market

The global breast reconstruction market report comprises players such as Mentor Worldwide LLC (Johnson & Johnson) (US), Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), and Silimed (Brazil) among others.

COVID-19 Analysis

A number of countries across the world has seen elective surgeries being postponed owing to the pandemic. Since breast reconstruction surgery is elective, this has affected the prospects of the market. Reconstructive procedures utilize additional resources and increase the risk of complications; depending on the procedure, they also raise the chance of needing equipment, resources, or materials such as a hospital bed and PPE. This procedure also requires a number of office visits for tissue expander fill or other complications.

The US is one such country that has seen a decline in elective procedures due to cancellation or delay. Various governments in European and Asia Pacific countries have also taken judgments to postpone elective procedures until the COVID-19 situation stabilizes. For example, in March 2020, UK NHS hospitals were told to suspend all non-urgent elective surgeries for at least three months. Adding to that, the US Surgeon General, the CDC, and many medical specialties like the American College of Surgeons and the American Society of Anesthesiologists suggested the temporary cancellation of elective surgical procedures. Physician and facility willingness to resume elective surgery will differ by geographic location. Moreover, more than 1,500 breast cancer patients in the UK face long waits to have reconstructive surgery after hospitals could not operate on them during the COVID-19 pandemic.

Recent Developments
  • 2022: Mentor Worldwide LLC (J&J) received the US FDA approval for a new Mentor Memory Gel boost breast implant.
  • 2021: POLYTECH Health & Aesthetic received US FDA approval for the company’s textured breast implants
  • 2020: Sientra received US FDA pre-market approval for its OPUS-branded breast implant products
Frequently Asked Questions

Q. How big is the breast reconstruction market?

Ans. The global breast reconstruction market size was USD 577 Million in 2021 and is anticipated to reach USD 748.1 Million in 2031, growing at a rate of 2.6% from 2022 to 2031.

Q. What is the breast reconstruction market growth rate?

Ans. The growth rate of the breast reconstruction market is 2.6% from 2022 to 2031.

Q. Which region holds a major market share for the breast reconstruction market?

Ans. North America holds a major market share of the breast reconstruction market in 2021.

Q. Which segment accounted for the largest breast reconstruction market share?

Ans. By products, the breast implants segment accounted for the largest breast reconstruction market share

Q. Who are the key players in the breast reconstruction market?

Ans. The global breast reconstruction market report includes players such as Mentor Worldwide LLC (Johnson & Johnson) (US), Allergan Aesthetics (an Abbvie company) (US), Ideal Implant Incorporated (US), Sebbin (France), GC Aesthetics (Ireland), POLYTECH Health & Aesthetics (Germany), Sientra (US), Integra Lifesciences (US), RTI Surgical Holdings (US), Establishment Labs S.A. (US), and Silimed (Brazil).

Q. What are the factors driving the breast reconstruction market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of breast cancer coupled with the growing rate of the aging population.

Q. What are the key growth strategies of breast reconstruction market players?

Ans. The key growth strategies of breast reconstruction market players are product launch and product approval.

Q. Which region will provide more business opportunities for the breast reconstruction market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for breast reconstruction market during the forecast period.

 

Read More
Single User License

Breast Lesion Localization Market
June, 2022

The global breast lesion localization market size was USD 254 million in 2021 and it is anticipated to reach USD 390.6 million in 2031, growing at a rate of 4.4% from 2022-2031.

Breast lesion localization is a medical device used in the detection of malignant and nonmalignant tumors. It is used in the preoperative marketing of nonpalatable breast lesions. There are different types f breast lesion localization devices developed using different techniques: radiations, wires, radar, and electromagnetic. Breast lesion localization methods are used to detect the abnormalities in terms of a lump or tumor in the breasts. There are various types of breast lesion localization methods used across the globe to detect a lump or tumor in the breasts. However, the rapid increase in the number of women opting for preventive screening tests for breast cancer creates a highly conducive environment for the growth of the breast lesion localization market.

Breast Lesion Localization Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$254 mn
Market Size in 2031$390.6 mn
Growth Rate (2021-31)4.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredType, Usage, and Region
Key CompaniesHologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The major factor boosting the growth of the market is the increasing incidence of breast cancer. Breast cancer is among the most common diseases affecting women in developed and developing countries. As per the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women globally. Worldwide, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the rising number of women undergoing cosmetic surgeries, such as breast enhancement.

Similarly, the growing rate of the aging population is also boosting the growth of the market. With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. As per the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. Conversely, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

Market Restraints & Challenges

One of the primary factors hindering the growth of the market is uncertainty in regulatory approval procedures. Regulatory agencies such as the US FDA require comprehensive clinical data supporting the clinical safety and efficacy of a product under approval. With the presence of stringent regulatory requirements for product approval, players operating in the breast lesion localization methods (specially radioisotope localization) market need to obtain nuclear regulatory clearance from the Nuclear Regulatory Commission to ensure the safe use of radioactive seeds. This approval process is very lengthy and capital-intensive, which makes it difficult for small manufacturers and companies with limited budgets to sustain themselves in this market.

Global Breast Lesion Localization Market Segmentation

The report analyses the breast lesion localization market based on type, usage, and region.

Global Breast Lesion Localization Market by Type

On the basis of type, it is segmented into wire localization, radioisotope localization, magnetic localization, electromagnetic localization, and other localization methods. The radioisotope localization segment is also sub-segmented into radio-guided occult lesion localization and radioactive seed localization. The wire localization segment is likely to dominate the market during the forecast period. The increasing incidence of breast cancer combined with the increasing adoption of expansion strategies by manufacturers of lesion localization products, product launches, and increasing healthcare expenditure are a major factor driving the global breast lesion localization market.

Global Breast Lesion Localization Market by Usage

On the basis of usage, it is segmented into breast biopsy and breast conservation (lumpectomy). The breast biopsy segment is likely to dominate the market during the forecast period. The key factors such as increasing consumption of alcohol and a sedentary lifestyle causing obesity are boosting the growth of the market.

Geographical Analysis of Global Breast Lesion Localization Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the global breast lesion localization market. The key factors such as high awareness about its diagnosis methods coupled with the huge women population suffering from cancer diseases boost the breast lesion localization market growth in the region.

Major Players of the Global Breast Lesion Localization Market

The global breast lesion localization market report includes players such as Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada), Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

COVID-19 Analysis

The impact of the COVID-19 pandemic and the lockdown is clearly visible in various industries, comprising the breast lesion localization market. The breast biopsy market observed a loss of business, and the trend continued till December 2020. The breast lesion localization market witnessed a short-term negative growth in 2020. Major regulatory authorities across the world (such as the CDC, the WHO, the MHRA, the TGA, and the EMA) have identified that breast cancer patients are at greater risk of COVID-19 infection than healthy adults. caregivers and hospitals are expected to witness delays in elective surgeries, screening procedures, and the number of breast lesion localization procedures. Still, the market started gradually rising from the late second half of 2020 owing to the increase in the number of biopsies resulting from clearing backlog as well as new cases and fully re-opened healthcare services. In 2021, with the launch of the vaccine against the COVID-19 virus, the patients’ options for elective surgeries increased.

Recent Developments
  • January 2021, Hologic Inc., has completed the acquisition of Somatex Medical Technologies, which will enable Hologic Inc to strengthen its breast markers portfolio.
  • October 2020, Endomagentics Ltd launched a product called Magseed, which is implanted in the affected breast prior to the surgery, and through the use of a probe, can point out to the surgeon where exactly the cancerous tissue is located.
  • January 2019, IZI acquired Cook’s product portfolio of soft-tissue biopsy and breast localization needles. This will enable IZI to capture newer markets.
  • November 2018, Merit Medical System Inc. has completed acquisition of Cianna Medical Inc. and its breast cancer localization and guidance devices, which adds to Merit, a technology leader in breast tumor localization.
Frequently Asked Questions

Q. How big is the breast lesion localization market?

Ans. The global breast lesion localization market size was USD 254 Million in 2021 and is anticipated to reach USD 390.6 Million in 2031, growing at a rate of 4.4% from 2022 to 2031.

Q. What is the breast lesion localization market growth rate?

Ans. The growth rate of the breast lesion localization market is 4.4% from 2022 to 2031.

Q. Which region holds a major market share for the breast lesion localization market?

Ans. North America holds a major market share of the breast lesion localization market in 2021.

Q. Which segment accounted for the largest breast lesion localization market share?

Ans. By type, the wire localization segment accounted for the largest breast lesion localization market share

Q. Who are the key players in the breast lesion localization market?

Ans. The global breast lesion localization market report includes players such as Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada), Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).

Q. What are the factors driving the breast lesion localization market growth?

Ans. The major factors driving the growth of the market are the increasing incidences of breast cancer coupled with the growing rate of the aging population.

Q. What are the key growth strategies of breast lesion localization market players?

Ans. The key growth strategies of breast lesion localization market players are product launch and product approval.

Q. Which region will provide more business opportunities for the breast lesion localization market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for breast lesion localization market during the forecast period.

Read More
Single User License

Blood Screening Market
June, 2022

The blood screening market size was USD 2.8 billion in 2021 and it is anticipated to reach USD 5.5 billion in 2031, growing at a CAGR of 6.9% from 2022-2031.

Blood screening is a medical process in which blood is examined for a specific disease or condition. It aids in monitoring disease and preventing health issue and a variety of other conditions such as infection and cancer. Human Immunodeficiency Virus (HIV), blood type, and pregnancy screenings are the most common types of blood screening.

Blood Screening Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$2.8 bn
Market Size in 2031$5.5 bn
Growth Rate (2021-31)6.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct & Service, Technology, End-User, and Region
Key CompaniesGrifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the market growth is an increasing number of blood donations across the globe. There is an increase in the need for donated blood owing to advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, like cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. On an average around 235 million major surgeries are being performed across the globe every year, of which 63 million are traumatic surgeries, cancer-related are over 31 million, and 10 million are related to pregnancy complications. Blood transfusion is generally prescribed in complicated childbirth to prepare for childhood congenital maternal blood disorders, acute anemia, and trauma.

Similarly, emerging markets such as India, the Middle East, and Africa offer promising opportunities for players in the blood screening industry owing to their rising disposable incomes and improving healthcare infrastructure. For example, according to Statista (August 2021), in 2017 India’s healthcare was worth about USD 160 billion, and it was anticipated to reach USD 372 billion by 2022 owing to rising income levels, increasing awareness about health, and the incidences of lifestyle diseases are growing year by year. Currently, the widely used technology in India is ELISA, because NAT registered relatively low penetration. Unlike the US, Canada, most of Europe, Japan, Korea, Singapore, Sri Lanka, the UAE, South Africa, Thailand, and China; NAT is still not mandatory in India. Almost 100 blood banks, comprising AIIMS, PGI Chandigarh, CMC Vellore, Medanta-The Medicity, and Narayana Hrudayalaya, are using NAT in ID-NAT format, whereas around 40 blood banks are using the pooling technique. So, an initiative is taken by the Indian government to train doctors, hospitals, and blood banks on using NAT.

Market Restraints & Challenges

One of the primary challenges in the growth of the global blood screening market is the alternative technologies. Digital immunoassays are a one-step solution for single-molecule detection without requiring washing steps based on ELISA using an array of femtoliter-sized wells. In this assay, a biomarker molecule is conjugated with an antibody-coated magnetic microparticle seeded in a well, amplified via an enzyme reaction, and detected with fluorescence. These tests have seen significant interest owing to the urgent and ever-increasing demand for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. So, a single-step, wash-free immunoassay for rapid and highly sensitive quantitative analysis of human serological IgG against SARS-CoV-2 has been developed, which requires only a single droplet of serum.

Global Blood Screening Market Segmentation

The report analyses the blood screening market based on product & service, technology, end user, and region.

Global Blood Screening Market by Product & Services

On the basis of product & services, it is segmented into reagents & kits, instruments, and software and services. The reagents and kits segment is likely to dominate the market during the forecast period 2022-2031. The increase in blood transfusion procedures leads to the higher consumption and frequent use of reagents & kits in blood screening procedures. Is boosting the growth of the market.

Global Blood Screening Market by Technology

Based on technology, it is segmented into the nucleic acid test, ELISA, rapid tests, western blot assays, and next-generation sequencing. The nucleic acid test segment is likely to dominate the market in 2021. The key factors such as increasing adoption of NAT technology owing to higher sensitivity over other blood donations are boosting the growth of the market.

Global Blood Screening Market by End User

Based on end user, it is segmented into blood banks and hospitals. The blood bank segment is likely to dominate the market during the forecast period. The increasing number of organ transplantation surgeries is boosting the growth of this segment during the forecast period.

Geographical Analysis of Global Blood Screening Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is accounted for the higher share of the blood screening market. The growth of the market is attributed to the increasing healthcare spending combined with the increasing prevalence of chronic disorders, the increasing healthcare spending, the increasing prevalence of chronic disorders, and the highly developed healthcare system in the US and Canada.

Major Players of the Global Blood Screening Market

The global blood screening market report comprises key players such as Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).

COVID-19 Analysis

The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The increased pressure owing to the growing rate of hospitalization of COVID-19 patients has led to the re-profiling of many hospitals and departments for treating patients with COVID-19. The COVID-19 outbreak led to curfews and lockdowns across the globe, leading to stalled blood donations, decreased/canceled collection drivers, and reduced demand for donated blood. It has mild-moderately affected the growth of the blood screening market. As stringencies with respect to curfews and social distancing become more liberal, the demand is expected to grow, creating a deficit in the market. However, governments across the globe are taking initiatives to increase donations during the forecast period to meet the sudden rise in demand following the lockdown.

Adding to that, the number of cancer patients are increasing which is also driving the need for donated blood. There is a need for blood and platelets during the treatment (chemotherapy) of cancer patients, blood replacement (for blood cancer patients), and surgery. As per the US National Center for Biotechnology Information (NCBI), cancer patients account for 20% to 30% of blood transfusions. As per the Leukemia & Lymphoma Society (2021), an expected combined total of 186,400 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021. This is expected further to drive the demand for the blood screening market.

Recent Developments
  • June 2021, Grail, announced the launch of the Galleri Blood test, the company’s innovative multi-cancer screening diagnostic capable of detecting the presence of multiple cancers. This test will help the company screen around 50 million people after its launch and pursue a full FDA approval by 2023.
  • May 2021, Tzar Labs, announced early detection cancer tests. This test will aid in determining the different stages of the disease and will be launched by the end of this year. The company’s accuracy rates are very high for screening of cancer and had shown results for all types of cancers.
  • May 2021, Beckmann Coulter launched the SARS-CoV-2-IgG test to assess antibody immune response levels.
  • September 2021, Roche Diagnostics acquired TIB Molbiol Group. This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
  • February 2020, BD acquired NAT Diagnostics, this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.
Frequently Asked Questions

Q. How big is the blood screening market?

Ans. The global blood screening market size was USD 2.8 billion in 2021 and is anticipated to reach USD 5.3 billion in 2031, growing at a rate of 6.9% from 2022 to 2031.

Q. What is the blood screening market growth rate?

Ans. The growth rate of the blood screening market is 6.9% from 2022 to 2031.

Q. Which region holds a major market share for the blood screening market?

Ans. North America holds a major market share of the blood screening market in 2021.

Q. Which segment accounted for the largest blood screening market share?

Ans. By end-user, the blood banks segment accounted for the largest blood screening market share

Q. Who are the key players in the blood screening market?

Ans. The global blood screening market report includes players such as Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).

Q. What are the factors driving the blood screening market growth?

Ans. The major factors driving the growth of the market are the high number of blood donations across the globe.

Q. What are the key growth strategies of blood screening market players?

Ans. The key growth strategies of blood screening market players are product launch and product approval.

Q. Which region will provide more business opportunities for the blood screening market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for blood screening market during the forecast period.

Read More
Single User License

Blood Culture Tests Market
June, 2022

The global blood culture devices market size was USD 4.5 billion in 2021 and it is anticipated to reach USD 8.5 billion in 2031, growing at a rate of 6.4% from 2022-2031.

Blood Culture tests play a essential role in the diagnosis of various infectious diseases. The increasing prevalence of infectious diseases combined with advancements in diagnostic technologies is anticipated to boost market growth. Adding to that, ageing population, demand for rapid analysis and treatment are estimated to fuel the blood culture tests market in future. According to the World Health Organization, every year around 17 million people around the world die owing to infectious diseases. Moreover, an increase in R&D investments and awareness in early diagnosis among the population across the globe is projected to foster the market growth in the near future. However, the lack of skilled professionals and high cost of novel technologies anticipated to hamper the market growth.

Blood Culture Tests Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$4.5 bn
Market Size in 2031$8.5 bn
Growth Rate (2021-31)6.4%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredType, Product, Technology, Application, End-User, and Region
Key CompaniesBecton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), bioMérieux SA (France), Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factors such as high incidence of blood stream infections is likely to boost the growth of the blood culture tests market. Nosocomial (hospital-acquired) bloodstream infections are one of the major causes of mortality across the world. In the US alone, approximately 250,000 cases of hospital-acquired BSIs occur each year. Worldwide, bloodstream infections affect about 30 million people leading to 6 million deaths, with 3 million newborns and 1.2 million children suffering from sepsis annually. In Eastern African countries, the proportion of patients with bloodstream infections is reported to range from 11% to 28%. In Ghana, bloodstream infection rates are estimated to be in the range of 9.3% to 11.2%. The occurrence of these infections raises the overall duration of hospitalization coupled with the cost of treatment. With the rising incidence of BSIs, the demand for advanced blood culture techniques that assist in the early detection of infections is expected to raise.

Likewise, emerging economies like China, India, and other countries in Southeast Asia and countries in the Middle East and Latin America are becoming focal points for the growth of the blood culture tests market. The major growth in these markets can primarily be attributed to the growth in the prevalence of infectious diseases, rapid growth in the geriatric population, the growing number of product approvals, and rising healthcare expenditure. For example, the healthcare expenditure in China increased to 5.35% of the GDP in 2018 from USD 4.88% of GDP in 2015. Such significant spending will result in the adoption of advanced systems, such as automated blood culture systems, among hospital and reference laboratories in these regions. This, in turn, is likely to provide potential growth opportunities for players operating in the blood culture tests market in the upcoming years.

Market Restraints & Challenges

One of the primary challenges in the growth of the global blood culture tests market is the high cost of automated instruments. Automated blood culture instruments are equipped with advanced features and functionalities and thus are priced at a premium. The cost of automated instruments such as PCR is approximately USD 10,000 to USD 15,000, and that of MALDI-TOF MS systems is around USD 150,000 to USD 850,000. Academic research laboratories generally cannot afford such high-cost systems as they have limited budgets. Adding to that, the maintenance costs and several other indirect expenses result in an increase in the total cost of ownership of these instruments. This is a major factor limiting the adoption of automated blood culture instruments, primarily among small-scale end users.

Global Blood Culture Tests Market Segmentation

The report analyses the blood culture tests market based on type, product, technology, application, end-user, and regions.

Global Blood Culture Tests Market by Type

On the basis of type, it is segmented into conventional/manual methods, and automated methods. The conventional/manual methods segment is likely to dominate the market during the forecast period. The key factors such as growing number of sepsis cases coupled with high cost of treatment is likely to boost the growth of the market. Similarly, rising geriatric population is also refueling the growth of the global blood culture tests market.

Global Blood Culture Tests Market by Product

On the basis of product, it is segmented into consumables, instruments, and software and services. The consumables segment is estimated to dominate the market during the forecast period 2022-2031. The key factors such as frequent demand of consumables as compared to instruments is the key factor driving the growth of this segment.

Global Blood Culture Tests Market by Technology

On the basis of technology, it is segmented into culture-based technology, molecular technologies, microarrays, PCR, PNA-FiSH, and proteomics technology. The culture-based technology segment is likely to dominate the market during the forecast period. The key factors such as increase in prevalence of infectious diseases, bloodstream infections, and sepsis, and surge in demand of diagnostic tests are the key factors that drive the growth of the market.

Global Blood Culture Tests Market by Application

On the basis of application, the market is segmented into bacteremia, fungemia, and mycobacterial detection. The bacteremia segment is likely to dominate the market during the forecast period. The increasing number of bloodstream infections and the rising number of sepsis cases across the globe is propelling the growth of the market.

Global Blood Culture Tests Market by End User

On the basis of end users, it is segmented into hospital laboratories, reference laboratories, academic research laboratories, and other laboratories. The hospital laboratories segment is likely to dominate the market during the forecast period. The key factors such as increasing aging population, rise in product approvals and launches combined with growing number of sepsis cases, high incidences of bloodstream infections, increase in demand for rapid diagnostic techniques and high prevalence of infectious diseases are boosting the growth of the market.

Geographical Analysis of Global Blood Culture Tests Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and Rest of the World. North America accounted for the largest share of the market. However, the Asia Pacific market is expected to register CAGR during the forecast period. The rise in awareness and acceptance of novel diagnostic method, strong economic growth, and increase in demand for advanced healthcare facilities are contributing towards the growth of the market.

Major Players of the Global Blood Culture Tests Market

The global blood culture tests market report includes such as Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), bioMérieux SA (France), Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US), Anaerobe Systems, Inc. (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), BINDER GmbH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio, Inc. (US), Axiom Laboratories (India), and HiMedia Laboratories Pvt. Ltd. (India)

COVID-19 Analysis:

The COVID-19 pandemic that began in Wuhan, China, has caused significant disruptions to businesses and economic activities across the globe. COVID-19 is anticipated to have a negative impact on the blood culture tests market owing to the limited or non-availability of medical facilities/treatment centers. To minimize the strain on the healthcare system and decrease disease transmission, governments across the globe are providing guidelines to postpone or delay non-essential medical and surgical procedures. Restrictions and lockdowns were also imposed in the areas of travel, business operations, public gatherings, health clubs, and fitness/wellness centers.

The COVID-19 pandemic has affected manufacturing and construction activities across the globe. Logistic limitations and reconsiderations of the raw material requirements are becoming a problem for manufacturers. Numerous manufacturers found themselves in situations where demand greatly exceeded supply, and therefore, many laboratories struggled to continue to offer testing in some regions. This negatively affected the blood culture tests market.

Recent Developments:
  • October 2021, Thermo Fisher Scientific and Q-Linea launched ASTar System, a rapid antimicrobial susceptibility testing system to produce true minimum inhibitory concentration (MIC) results in 6 hours.
  • March 2020, Mangolia Medical Technologies announced that it received clearance from U.S. regulators for its expanded line of blood contamination reduction products, comprising Steripath Gen2 Initial Specimen Diversion Device.
  • February 2020, BD (US), had an agreement with Babson Diagnostics (US). The companies signed an agreement to enable small-volume blood collection for diagnostic testing in retail settings.
  • April 2019, bioMerieux SA, partnered with Wellcome Trust (UK), to coordinate VALUE-Dx, a European public-private partnership to fight antimicrobial resistance through diagnostics.
Frequently Asked Questions

Q. How big is the blood culture tests market?

Ans. The global blood culture tests market size was USD XX billion in 2021 and is anticipated to reach USD XX billion in 2031, growing at a rate of XX% from 2022 to 2031.

Q. What is the blood culture tests market growth rate?

Ans. The growth rate of the blood culture tests market is XX% from 2022 to 2031.

Q. Which region holds a major market share for the blood culture tests market?

Ans. North America holds a major market share of the blood culture tests market in 2021.

Q. Which segment accounted for the largest blood culture tests market share?

Ans. By end-user, the hospital laboratories segment accounted for the largest blood culture tests market share

Q. Who are the key players in the blood culture tests market?

Ans. The global blood culture tests market report includes players such as Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), bioMérieux SA (France), Luminex Corporation (US), Danaher Corporation (US), Bruker Corporation (US), IRIDICA (US), Roche Diagnostics (Switzerland), T2 Biosystems, Inc. (US), Anaerobe Systems, Inc. (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany), Nikon Corporation (Japan), BINDER GmbH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio, Inc. (US), Axiom Laboratories (India), and HiMedia Laboratories Pvt. Ltd. (India).

Q. What are the factors driving the blood culture tests market growth?

Ans. The major factors driving the growth of the market are the high incidence of bloodstream infections and growing demand for rapid diagnostic techniques.

Q. What are the key growth strategies of blood culture tests market players?

Ans. The key growth strategies of blood culture tests market players are product launch and product approval.

Q. Which region will provide more business opportunities for the blood culture tests market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for blood culture tests market during the forecast period

Read More
Single User License

Blood Collection Devices Market
June, 2022

The global blood collection devices market size was USD 5.9 billion in 2021 and it is anticipated to reach USD 10.8 billion in 2031, growing at a rate of 6.3% from 2022-2031.

Blood collection devices help in the safe withdrawal of blood. Blood is collected from donors to perform various diagnostic tests. Needles & rings, lancets, and other devices are used for arterial and venous blood collection. Arterial blood collection has certain advantages like arterial blood gas sampling and intraoperative blood salvage. However, the growing number of accidents & trauma cases, rising incidence of infectious disease, and the developing liquid biopsy technology have improved associated healthcare processes. However, the shortage of qualified personnel will impede the market growth. Moreover, the growth opportunities among emerging nations are likely to offer significant opportunities for the growth of the global blood collection devices market.

Blood Collection Devices Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$5.9 bn
Market Size in 2031$10.8 bn
Growth Rate (2021-31)6.3%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Method, End-User, and Region
Key CompaniesBecton, Dickinson and Company (US), , Haematonics (US), Terumo BCT (US), Fresenius Kabi AG (Germany), Grifols, S.A. (Spain), Nipro Medical Corporation (Japan), Greiner Holding (Austria), Quest Diagnostics (US), SARSTEDT AG & Co. (Germany), Macopharma (France)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The major factor boosting the growth of the market is the increasing prevalence of infectious diseases with the emergence of newer pathogens and chronic & lifestyle diseases. The increasing prevalence of infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV), malaria, syphilis, and brucellosis are a major factor driving the demand for effective blood collection (owing to the risk of disease transmission during blood transfusion). According to the WHO, (July 2021), there were an estimated 37.7 million [30.2–45.1 million] people living with HIV at the end of 2020, over two-thirds of whom (25.4 million) are in the WHO African Region. In 2020, 680,000 [480,000–1.0 million] people died from HIV-related causes, and 1.5 million [1.0–2.0 million] people acquired HIV. Adding to that, according to the WHO (July 2021), worldwide, there were an estimated 7 million new syphilis infections in 2020.

The burden of chronic diseases is rapidly increasing across the globe. Almost half of the total chronic disease deaths are attributable to cardiovascular disease (CVD). In the US alone, as per the American Heart Association, the prevalence of CVD is projected to increase from 36.9% in 2010 to 38.7% by 2020 and 40.5% by 2030. Obesity coupled with diabetes is also showing worrying trends because they already affect a large proportion of the population and because they have started to appear earlier in life. The prevalence of lifestyle diseases is also growing across the world, particularly in emerging countries.

This scenario has ensured greater adherence to health check-ups combined with the growing importance of markers to find disease conditions mainly via blood collection. Health check-ups are gaining popularity both at a personal level as well as performed at a corporate level for employee well-being. This will be favorable for the market growth and a significant contributor to the blood collection devices market, as blood tests are a primary approach to diagnosing these diseases.

Market Restraints & Challenges

One of the primary challenges in the growth of the global blood collection devices market is the high cost of automated blood collection devices. For blood banks, capital investments in automated blood collection using apheresis devices are very high in comparison to that of whole-blood collection. The average price for devices ranges between USD 45,000 and USD 55,000. So, smaller blood banks and hospitals do not opt for this type of blood collection. The cost of therapeutic apheresis is also very high, as it comprises the additional cost of disposables—between USD 1,500 and USD 3,000 per patient. Due to their high costs, the adoption of these automated blood collection products is very minimal as compared to manual blood collection products in countries such as China and India. This is limiting the overall growth of the blood collection devices market.

The cost of providing apheresis therapy is a matter of almost universal concern. Estimates of costs of individual apheresis treatments are very much available but vary widely. For example, in the US, the cost of an apheresis procedure is approximately USD 2,500 per treatment. An investment of USD 19,000 to USD 32,000 for a blood cell separator is the initial cost for setting up the machine, and disposable sets produced by manufacturers will vary between USD 40 and USD 90 per treatment. Replacement fluids (at an average volume of 2.8 liters), like albumin or fresh frozen plasma, make up the remainder of the costs, running from USD 125 to USD 600 per treatment.

Global Blood Collection Devices Market Segmentation

The report analyses the blood collection devices market based on product, method, end-user, and regions.

Global Blood Collection Devices Market by Product

On the basis of product, it is segmented into blood collection tubes, needles and syringes, and others. The key factors such as the strong prevalence of chronic diseases combined with technological advancements in blood collection devices are boosting the growth of the segment during the forecast period. Blood collection tubes witnessing a great demand owing to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders, cancers such as leukaemia, lymphoma, myeloma, and myelodysplastic syndrome can affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system.

Global Blood Collection Devices Market by Method

Based on the method, it is segmented into manual blood collection and automated blood collection. The key factors such as a steady increase in the number of patients suffering from these diseases and ailments and the growing number of accidents may boost the blood collection market during the forecast period. The manual blood collection segment is likely to dominate the market during the forecast period. The increasing number of accidents, as well as trauma cases worldwide, will witness lucrative growth opportunities during the forecast period.

Global Blood Collection Devices Market by End User

Based on end-users, it is segmented into hospitals & clinics, diagnostic & pathology centers, blood banks, and others. Surging incidence of infectious diseases comprising hepatitis, human immunodeficiency virus (HIV), tuberculosis, and human papillomavirus (HPV) among others will boost the demand for blood collection production. Moreover, the rising prevalence of lifestyle diseases across the globe enhances the growth of the market. The hospitals & clinics segment is likely to dominate the market during the forecast period. The key factors such as increasing demand for blood donations are also fuelling the demand of the blood collection devices market. For example, according to WHO, 112.5 million blood donations collected globally and there is an increase of 10.7 million blood donations from unpaid donors has been reported from 2008 to 2013.

Geographical Analysis of Global Blood Collection Devices Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America (comprising the US and Canada) accounted for the largest share of the global blood collection devices, followed by Europe. Factors like the increasing prevalence of lifestyle diseases and the rising incidence of blood disorders, better healthcare facilities, and the presence of major manufacturers in the region are stimulating the growth of the blood collection devices market in North America.

Major Players of the Global Blood Collection Devices Market

The global blood collection devices market report includes players such as Becton, Dickinson and Company (US), Haematonics (US), Terumo BCT (US), Fresenius Kabi AG (Germany), Grifols, S.A. (Spain), Nipro Medical Corporation (Japan), Greiner Holding (Austria), Quest Diagnostics (US), SARSTEDT AG & Co. (Germany), Macopharma (France), Smiths Medical (US), Cardinal Health (US), Retractable Technologies (US), Liuyang Sanli Medical Technology Development (China), F.L. Medical S.R.L (Italy), AB Medical (South Korea), APTCA SPA (Italy), Jiangsu Micsafe Medical Technology CO., LTD. (China), Disera Tibbi Malzeme Lojistik Sanayi Ve Ticaret A.Þ (Turkey), Ajosha Bio Teknik Pvt. Ltd. (India), Preq Systems (India), CML Biotech (India), Lmb Technologie GmbH (Germany), Mitra Industries Private Limited (India) and Neomedic Limited (UK).

COVID-19 Analysis

The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the blood collection devices market. Both hospital and independent laboratories are generally reviewing each test to decide whether to recommend consultations with laboratory hematologists for tests with a higher risk profile or not to offer tests that could not be performed safely. This affected the market negatively in the initial period of the pandemic, reducing the use of blood collection devices. Conversely, increasing caution and the rising testing volumes, along with the need for regular health and body check-ups will ensure market growth in a later phase.

Results now take an average of four to six days for the general population, much longer than the two to three days required before. This is because tests for hospital patients and symptomatic healthcare workers are prioritized and take one day on average, which has resulted in a delayed cycle. While it has affected market growth to some extent, the situation is expected to change for the better.

Recent Developments
  • February 2022, Abacus dx launched the newest addition to Streck’s trusted blood collection tube portfolio, RNA Complete BCT.
  • February 2022, BD has released UltraSafe Plus 2.25 mL, a new needle guard solution that improves the delivery of drugs and other biologic solutions,
  • August 2021, Quest Diagnostics Incorporated has acquired Boca Raton based Nationwide Laboratory Services. With the acquisition, Quest will broaden access to diagnostic innovation and insights empowering better health for more communities in South Florida.
  • June 2021, Greiner Bio-One introduced MiniCollect PIXIE Heel Incision Safety lancet for expanding its portfolio with a new safety lancet specially designed for heel incision and now has three different lancet types of offers to cover individual needs.
  • April 2021, Terumo Blood an Cell Technologies and CSL Plasma announced collaboration to deliver a new plasma collection platform.
  • November 2020, Intravactechnology OU introduced new packaging system for its blood collection devices set. The packaging is available in paper, plastic blister, and foil pack for 1,2, and 5 tube pack.
  • July 2020, Mangolia Medical launched Steripath Gen 2 with integrated syringe, addressed to the patient with difficult intravenous access or the ‘hard stick’ patient population.
Blood Collection Devices Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global blood collection devices market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of aspects that boost and restrict the development of the market is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future blood collection devices market potential from 2021 to 2031 in terms of revenue.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global blood collection devices industry.
Frequently Asked Questions

Q. How big is the blood collection devices market?

Ans. The global blood collection devices market size was USD 5.9 billion in 2021 and it is anticipated to reach USD 10.8 billion in 2031, growing at a rate of 6.3% from 2022-2031.

Q. What is the blood collection devices market growth rate?

Ans. The growth rate of the blood collection devices market is 6.3% from 2022 to 2031.

Q. Which region holds a major market share for the blood collection devices market?

Ans. North America holds a major market share of the blood collection devices market in 2021.

Q. Which segment accounted for the largest blood collection devices market share?

Ans. By end-user, the hospital’s segment accounted for the largest blood collection devices market share

Q. Who are the key players in the blood collection devices market?

Ans. The global blood collection devices market report includes players such as Becton, Dickinson and Company (US), Haematonics (US), Terumo BCT (US), Fresenius Kabi AG (Germany), Grifols, S.A. (Spain), Nipro Medical Corporation (Japan), Greiner Holding (Austria), Quest Diagnostics (US), SARSTEDT AG & Co. (Germany), Macopharma (France), Smiths Medical (US), Cardinal Health (US), Retractable Technologies (US), Liuyang Sanli Medical Technology Development (China), F.L. Medical S.R.L (Italy), AB Medical (South Korea), APTCA SPA (Italy), Jiangsu Micsafe Medical Technology CO., LTD. (China), Disera Tibbi Malzeme Lojistik Sanayi Ve Ticaret A.Þ (Turkey), Ajosha Bio Teknik Pvt. Ltd. (India), Preq Systems (India), CML Biotech (India), Lmb Technologie GmbH (Germany), Mitra Industries Private Limited (India) and Neomedic Limited (UK).

Q. What are the factors driving the blood collection devices market growth?

Ans. The major factors driving the growth of the market are the increasing volume of surgeries and the growing prevalence of severe trauma injuries.

Q. What are the key growth strategies of blood collection devices market players?

Ans. The key growth strategies of blood collection devices market players are product launch and product approval.

Q. Which region will provide more business opportunities for the blood collection devices market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for blood collection devices market during the forecast period

Read More
Single User License

Bone Growth Stimulators Market
June, 2022

The bone growth stimulators market size was 1 billion in 2021 and it is anticipated to reach USD 2 billion in 2031, growing at a CAGR of 7.0% from 2022-2031.

Bone Growth stimulators are devices that are used to boost the healing process during the treatment of the ailments such as spinal fixation, and orthopedic fixation. Bone growth stimulators work on all kinds of fractures such as fresh fractures, fractures healing slowly or not at all, and fractures with an elevated risk. It can also be used as supportive therapy after surgery on a fracture and in the corrective osteotomy. Bone Growth Stimulator enhances the healing process by stimulating the production of new cells, which will allow your fracture to heal considerably faster. Bone growth stimulators are the perfect treatment approach when the patient is not comfortable with the surgical procedure and wants to avoid it. Also, as it fastens the healing process, it helps patients get back to their feet quickly. Bone growth stimulators have revolutionized the treatment of bone fractures and spinal fusions and are becoming an important tool in the healing process. Advantages over surgical procedures, faster recovery time, and increasing patient preference are factors that contribute to the growth of the bone growth stimulator market.

Bone Growth Stimulators Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$1 bn
Market Size in 2031$2 bn
Growth Rate (2021-31)7.0%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Application, End-User, and Region
Key CompaniesOrthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The key factor boosting the growth of the market is the growing patient preference for non-invasive and minimally invasive surgical treatments. The demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key advantages of minimally invasive procedures comprise fewer complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infections, reduced postoperative care, and quicker recovery. Minimally invasive procedures make use of advanced technologies to diagnose and treat various diseases, comprising cancer. These procedures are used as an effective approach for removing cancer tumors and lymph nodes without scarring.

Similarly, emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities in the bone growth stimulators market. Factors such as the presence of a large patient population, rising healthcare expenditure, government initiatives to support the healthcare industry, strengthening export trade, and growing awareness among physicians, surgeons, and patients about the latest treatment options for spinal fusion and bone healing are expected to boost the demand for bone growth stimulation products in these countries. In addition, owing to the significant cost advantages, many patients from developed markets are reported to travel to these emerging markets to undergo medical treatment.

Market Restraints and Challenges

The primary factor hampering the growth of the bone growth stimulators market is limited medical reimbursement for bone stimulation products. Medical reimbursement is among the major factors that affect the adoption and demand of specific diagnostic or therapeutic products among patients and healthcare providers at a country level. A majority of healthcare insurance providers in mature countries (such as the US and Australia) cover bone growth stimulation products under specific criteria. For instance, in the US, bone growth stimulation devices are covered under insurance if target bones are separated by less than 1 centimeter or are non-infected. Medicare (US) also covers bone growth stimulation devices under Part B schedule and offers device rent on prescription for specified indications. Similarly, the Transport Accident Commission (Australia) provides funding for implantable or externally applied bone growth stimulation equipment in case of transport accident injuries in the country. However, many private insurance providers do not include insurance or reimbursement for bone growth stimulation surgeries.

Global Bone Growth Stimulators Market Segmentation

The report analyses the bone growth stimulators market based on product, application, end user, and region.

Global Bone Growth Stimulators Market by Product

On the basis of the product, it is segmented into bone growth stimulation devices, bone morphogenic proteins, and platelet-rich plasma. The bone growth stimulation devices segment accounted for the bone growth stimulators market. This can be attributed to the growing geriatric population, rising preference for non-surgical treatment procedures, and growing prevalence of nonunion fractures. Adding to that, obesity, smoking, and diabetes, among other factors, can delay or inhibit bone healing after surgery or trauma. The growing incidence of these risk factors will further help the market growth.

Global Bone Growth Stimulators Market by Application

On the basis of the application, it is segmented into spinal fusion surgeries, delayed union and nonunion bone fractures, oral and maxillofacial surgeries, and others. Spinal fusion surgeries are conducted to connect two or more vertebrae permanently and eliminate motion between them. Bone growth stimulation products are used at the time or post-surgery for stimulating the natural bone growth process. The growth of this segment can be attributed to the increasing population, the growing number of spine procedures, the established safety and efficacy of stimulators in fusion surgery, and the increasing use of bone growth stimulation products.

Global Bone Growth Stimulators Market by End User

On the basis of the end users, it is segmented into hospitals & ASC’s, home care settings, and academic & research institutes. The hospitals & ASCs accounted for the largest share of the bone growth stimulators market. The advantages of bone growth stimulation products over their counterparts, the growing prevalence of spinal disorders, and growing awareness of bone growth stimulation products are the key factors boosting the bone growth stimulators markets for hospitals and ASC’s.

Geographical Analysis of Global Bone Growth Stimulators Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the largest share of the bone growth stimulators market. It is attributed to the highly developed healthcare infrastructure and reimbursement system in the region and growing physician and patient awareness about the newly introduced treatment procedures and technologies in the market. The rising incidence of spinal disorders, increasing geriatric population, growing population exposure to key risk factors such as obesity, smoking, and diabetes, and rising patient preference for minimally invasive orthopedic therapies are further boosting the growth of the market.

Market Players of the Global Bone Growth Stimulators Market

The global bone growth stimulators market report comprises key players such as Orthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health Inc. (Canada), VQ OrthoCare (US), Kinex Medical Company, LLC (US), Fintek Bio-Electric Inc. (Canada), Biomedical Tissue Technologies Pty Ltd. (Germany), T-Biotechnology (Turkey), DrPRP America LLC (US), Ivy Sports Medicine, LLC (US), Glofinn Oy (Finland), and REMI GROUP (India) among others.

COVID-19 Analysis

The pandemic is anticipated to have a short-term negative impact on the bone growth stimulators market owing to a sharp decline in elective surgeries, ban on organized sports, temporary closure of O&P clinics, hospital access restricted to non-essential care, and limited access to clinics, and slow-down in-patient flow and referrals. However, gradual signs of recovery can be seen in key European markets as well as China. It is expected that the market will begin to gradually rise as expected from the late second half of 2021, which could be attributed to addressing pre-COVID elective surgeries, the growing number of surgeries resulting from clearing backlogs as well as new cases, fully reopened healthcare services, recreation, and physical work resumed on a large scale and the reopening of organized sports. Moreover, long-term growth drivers like an increase in the geriatric population and the rising prevalence of diabetes, obesity, and osteoarthritis will continue to play a major role in the growth of the market during the forecast period.

Recent Developments
  • April 2021, Orthofix entered into an exclusive license agreement to commercialize the innovative portfolio of IGEA’s bone, cartilage, and soft tissue stimulation products in the US and Canada.
  • March 2021, Bioventus LLC announced the acquisition of Bioness, Inc. This acquisition will enable Bioventus LLC to expand its bone growth therapy product portfolio.
  • November 2020, Stryker acquired Wright Medical for USD 5.4 billion. The acquisition strengthened Stryker’s position in the orthopedics devices market.
  • June 2020, DePuy Synthes renewed its agreement with AO Foundation to improve patient care and outcome through innovation and AO’s independent global education offerings.
  • February 2020, Orthofix Medical Inc. received US FDA approval for its STIM on Track, mobile app version 2.1 to advance the treatment with its bone growth stimulators like Cervical Stim, Spinal Stim, and Physio Stim.
  • January 2020, Medtronic acquired Stimgenics to expand its portfolio in the Differential Target Multiplexed Spinal Cord Stimulation Therapy.
Frequently Asked Questions

Q. How big is the bone growth stimulators market?

Ans. The global bone growth stimulators market size was USD 1 billion in 2021 and is anticipated to reach USD 2 billion in 2031, growing at a rate of 7.0% from 2022 to 2031.

Q. What is the bone growth stimulators market growth rate?

Ans. The growth rate of the bone growth stimulators market is 7.0% from 2022 to 2031.

Q. Which region holds a major market share for the bone growth stimulators market?

Ans. North America holds a major market share of the bone growth stimulators market in 2021.

Q. Which segment accounted for the largest bone growth stimulators market share?

Ans. By end-user, the hospital & ASC’s segment accounted for the largest bone growth stimulators market share.

Q. Who are the key players in the bone growth stimulators market?

Ans. The global bone growth stimulators market report includes players such as Orthofix Medical, Inc. (US), DJO Finance, LLC (US), Zimmer Biomet (US), Bioventus LLC (US), Medtronic plc (Ireland), Stryker (US), DePuy Synthes (US), Arthrex, Inc. (US), Isto Biologics (US), Terumo Corporation (Japan), Ember Therapeutics, Inc. (US), Ossatec Benelux Ltd. (Netherlands), Altis Biologics (Pty) Ltd. (South Africa), Regen Lab SA (Switzerland), ITO Co., Ltd. (Japan), Elizur Corporation (US), BTT Health GmbH (Germany), Stimulate Health Inc. (Canada), VQ OrthoCare (US), Kinex Medical Company, LLC (US), Fintek Bio-Electric Inc. (Canada), Biomedical Tissue Technologies Pty Ltd. (Germany), T-Biotechnology (Turkey), DrPRP America LLC (US), Ivy Sports Medicine, LLC (US), Glofinn Oy (Finland), and REMI GROUP (India) among others.

Q. What are the factors driving the bone growth stimulators market growth?

Ans. The major factors driving the growth of the market are the rising burden of bone and joint disorders coupled with the development of biocompatible synthetic bone grafts.

Q. What are the key growth strategies of bone growth stimulators market players?

Ans. The key growth strategies of bone growth stimulators market players are product launch and product approval.

Q. Which region will provide more business opportunities for the bone growth stimulators market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for bone growth stimulators market during the forecast period

Read More
Single User License

Aspiration & Biopsy Needles Market
June, 2022

The global aspiration & biopsy needles market size was USD 889 Mn in 2021 and is anticipated to reach USD 1,901 Mn in 2031, growing at a rate of 7.9% from 2022 to 2031.

A needle biopsy is a procedure to obtain a sample of cells from the body for laboratory testing. Common needle biopsy procedures comprise fine-needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones, and other organs, such as the liver or lungs. The sample from needle biopsy may assist the doctor to determine what’s causing a mass or lump, an infection, and inflammation. One may undergo imaging tests, such as the computerized tomography (CT) scan or an ultrasound, before needle biopsy. Sometimes these tests are used during the needle biopsy procedure to more accurately locate the area to be biopsied.

Scope of the Report
Report Attribute Details
Market Size in 2021$889 Mn
Market Size in 2031$1,901 Mn
Growth Rate (2021-31)7.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct Type, Application, Procedure, End User, and Regions
Key CompaniesCONMED Corporation, Medtronic Plc, Olympus Corporation, Becton, Dickinson and Company, Boston Scientific Corporation, Cook Group Incorporated, Argon Medical Devices, Inc, INRAD Inc
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Global Aspiration & Biopsy Needles Market Drivers

Rising prevalence of cancer

Worldwide, there has been a significant rise in the number of people suffering from cancer. This can be indorsed to a number of factors, like lifestyle changes, unhealthy diets, and growing tobacco consumption. According to estimates from the International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths across the globe. By 2040, the global burden is anticipated to grow to 27.5 million new cancer cases and 16.3 million cancer deaths, majorly due to the growth and aging of the population.

The incidence of cancer is the highest in more-developed regions, but mortality is relatively higher in less-developed countries owing to a lack of access to treatment facilities coupled with the lack of awareness regarding the benefits of early detection. According to the American Cancer Society, about 9.6 million people die from cancer every year, and 70% of cancer deaths occur in low-to-middle income countries like China and India; these proportions are expected to grow further by 2025. With the increasing prevalence of cancer in major regions across the globe, the demand for effective cancer diagnosis is anticipated to increase in the upcoming years. This, in turn, is expected to support the growth of the aspiration and biopsy needles market during the forecast period.

Global Aspiration & Biopsy Needles Market Opportunities

Emerging economies

Emerging economies (such as India, China, Brazil, and Mexico) are anticipated to offer significant growth opportunities for players operating in the aspiration and biopsy needles market. This can be attributed to improvements in the standard of living, the presence of a huge target population base (as a result of the rising prevalence of cancer), improvements and developments in the healthcare infrastructure, rising healthcare expenditure, and the transformation of healthcare research facilities in these countries. Adding to that, the rapid economic development coupled with rising healthcare expenditure in these emerging countries have improved access to quality healthcare, including quality cancer care.

Global Aspiration & Biopsy Needles Market Restraints

Risk of infection associated with the use of aspiration and biopsy needles

Biopsy needle procedures, like core-needle and fine-needle procedures, assist radiologists and surgeons in examining abnormalities at a particular site. Conversely, patients can contract infections during these procedures as they involve cuts and incisions for extracting tissue samples. Moreover, in several cases, aspiration and biopsy needles are reused, which further increases the risk of infection during these procedures. Even though the reuse of some needles is not recommended by healthcare authorities as well as product manufacturers, this practice is still prevalent, especially in developing economies, which is likely to hamper the growth of the market.

Impact of COVID-19 on Aspiration & Biopsy Needles Market

The COVID-19 pandemic has resulted in a significant drop in cancer screening, cancer management visits, and cancer biopsy procedures worldwide. As a result of forced lockdowns, cancer screening services were disrupted to some extent, which ultimately minimized the demand for biopsy needles. The repercussions of delayed cancer detection owing to COVID-19 were investigated in a study undertaken in the UK and published in Lancet Oncology in March 2021. The study covered data from over 100,000 people with breast, colorectal, oesophageal, or lung cancer. It found that 1- and 5-year cancer survival rates will be severely reduced because of the outbreak of COVID-19, due to the reduction in diagnostic biopsies and lack of availability of screening services. Conversely, numerous physician reports from the US have observed a growing number of screening appointments during the last quarter of 2020, which is expected to boost continually.

Global Aspiration & Biopsy Needles Market Segmental Analysis

The report covers the aspiration and biopsy needles market by product type, application, procedure, end-user, and region.

Global Aspiration & Biopsy Needles Market by Product Type

The various product type comprised in the global aspiration & biopsy needles market are biopsy needles and aspiration needles. The biopsy needles segment is also sub-segmented into CNB needles and VAB needles.

The biopsy needle segment is likely to dominate the market during the forecast period. The key factors such as the rising prevalence of cancer coupled with an increasing preference for minimally invasive diagnostic procedures (over excision biopsies) are boosting the growth of the biopsy needles segment in the global aspiration & biopsy needles market.

Global Aspiration & Biopsy Needles Market by Application

The different applications comprised in the global aspiration & biopsy needles market are tumor/cancer application, wound application, and other applications. The tumor/cancer application segment is also sub-segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, kidney cancer, bone & bone marrow cancer, and other cancer.

The tumor/cancer segment is likely to dominate the market during the forecast period. The higher market share is primarily attributed to the growing prevalence of breast cancer combined with rising awareness about the disease, and increasing research activity pertaining to breast screening and diagnosis is boosting the market share of the segment.

Global Aspiration & Biopsy Needles Market by Procedure

The various procedures such as image-guided procedures, ultrasound-guided procedures, stereotactic procedures, CT-guided procedures, MRI-guided procedures, other image-guided procedures, and nonimage-guided procedures are comprised in the global aspiration & biopsy needles market.

The image-guided procedure accounted for the largest share of the market during the forecast period. The key factors propelling the market growth are the rising preference for minimally invasive biopsy and aspiration procedures.

Global Aspiration & Biopsy Needles Market by End User

The various end-users comprised in the global aspiration & biopsy needles market are hospitals & surgical centers, diagnostic clinics & pathology laboratories, ambulatory care centers, and research & academic institutions.

The hospitals & surgical centers segment is likely to dominate the market during the forecast period. The key factors such as the rising prevalence of cancer coupled with cancer awareness initiatives undertaken by government and global health organizations are boosting the growth of the market.

Geographical Analysis of Global Aspiration & Biopsy Needles Market

The global aspiration & biopsy needles market is analyzed for various key countries of the regions such as North America, Europe, Asia Pacific, and the Rest of the World.

The Asia Pacific is likely to hold the majority of the market share during the forecast period. The increasing initiatives by the government for cancer diagnostic and screening combined with rising research activity and the high incidence of cancer in Asia Pacific countries such as India and China are the major driving factors for the growth of the market.

Market Players of Global Aspiration & Biopsy Needles Market

The key players in the global aspiration & biopsy needles market are CONMED Corporation, Medtronic Plc, Olympus Corporation, Becton, Dickinson and Company, Boston Scientific Corporation, Cook Group Incorporated, Argon Medical Devices, Inc, INRAD Inc., Somatex Medical Technologies, Stryker Corporation, Cardinal Health, Remington Medical, Ranfac Corporation, HAKKO CO., LTD, and Merit Medical Systems among others.

Key Developments in Global Aspiration & Biopsy Needles Market
  • December 2021: Olympus launched the FDA 510(k)- cleared BF-UC190F endobronchial ultrasound (EBUS) bronchoscope.
  • January 2021: Hologic Inc. acquired Somatex Medical Technologies, Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care.
  • May 2019: Argon Medical acquired Mana tech Ltd., its exclusive distributor for the UK and Ireland.

 

Why GIS?

Read More
Single User License

Artificial Cornea and Corneal Implant Market
June, 2022

The global artificial cornea and corneal implants market size was USD 420 Mn in 2021 and is anticipated to reach USD 752 Mn in 2031, growing at a rate of 6.0 % from 2022 to 2031.

A cornea transplant (keratoplasty) is a surgical procedure to substitute part of the cornea with corneal tissue from a donor. The cornea is the transparent, dome-shaped surface of the eye. It’s where light enters the eye and is a large part of the eye’s ability to see clearly. A cornea transplant may restore vision, reduce pain, and improve the appearance of a damaged or diseased cornea. Most cornea transplant procedures are successful. But cornea transplant carries a small risk of complications, like the rejection of the donor cornea.

Scope of the Report
Report Attribute Details
Market Size in 2021$420 Mn
Market Size in 2031$752 Mn
Growth Rate (2021-31)6.0%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredType, Transplant Type, Disease Indication, End User, and Regions
Key CompaniesAJL Ophthalmic, CorneaGen Inc, CorNeat Vision, LinkoCare Life Sciences AB, Presbia plc, Mediphacos, Aurolab, Cornea Biosciences, DIOPTEX GmbH and EyeYon Medical
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Global Cornea and Corneal Implants Market Drivers

Increasing Prevalence of eye diseases

The number of people with major eye diseases is increasing worldwide, and vision loss is becoming a major public health concern. The growth in the aging population coupled with the increasing prevalence of chronic disorders like diabetes and hypertension have raised the prevalence of eye diseases such as diabetic retinopathy and ocular hypertension (glaucoma). The number of blind individuals or those affected with low vision is also expected to increase extensively. According to the Royal National Institute of Blind People (RNIB), in 2013, around 2 million people in the UK were living with vision loss, and this figure is likely to increase to 4.1 million by 2050. Presently, there are 146 million people worldwide with trachoma, of which 10 million suffer from trichiasis and need surgery to prevent corneal blindness and 4.9 million individuals are completely blind from trachomatous corneal scarring. Moreover, as per the “World Report on Vision 2019” by WHO, nearly 2.2 people worldwide have vision impairment or blindness. This figure includes several eye conditions that include moderate to severe distance vision impairment or blindness owing to unaddressed refractive errors (123.7 million) and presbyopia (1.8 billion, including both addressed and unaddressed presbyopia), age-related macular degeneration (10.4 million), cataract (65.2 million), corneal opacities (4.2 million), glaucoma (6.9 million), trachoma (2 million), diabetic retinopathy (3 million), and other causes (37.1 million), and people with mild vision impairment with unknown causes (188.5 million).

Global Cornea and Corneal Implants Market Opportunities

Shortage of corneal donors

There is a significant requirement for corneal donors across the globe, as approximately 10 million people need corneal transplants. Densely populated counties such as India suffer from a significant shortage of donor corneas, and there is a waiting period of more than six months for corneal transplants among patients suffering from corneal blindness. Approximately 6.8 million people in the country have poor vision in one eye, and nearly one million people have poor vision in both eyes due to corneal disorders. It was anticipated that by the end of 2020, India would suffer from 10.6 million cases of unilateral corneal blindness. In 2019, around 120,000 people were affected by corneal blindness. About 250,000 corneas are needed annually in the country; still, the total number of corneas donated each year is around 25,000. The high burden of corneal blindness, combined with a shortage of corneal donors, is likely to offer high-growth opportunities to manufacturers of corneal implants.

Global Cornea and Corneal Implants Market Restraints

High cost of ophthalmology devices and surgical procedures

Technological advancements in ophthalmic lasers, like the development of femtosecond lasers, have reduced surgery times and improved procedural outcomes and convenience. But, the high cost of these instruments is expected to restrain their growth. According to a study conducted by the Singapore Eye Research Institute (SERI), the cost of a femtosecond laser was USD 400,000–USD 550,000. This affects their adoption among end users, as it is difficult to estimate the number of patients choosing femtosecond laser therapy over conventional methods and whether the number of patients choosing the therapy will cover the installation cost of the laser. Likewise, the cost of an OCT ranges from USD 70,000 to USD 120,000, and the cost of new fundus machines range from USD 15,000 to USD 60,000.

Impact of COVID-19 on Cornea and Corneal Implant Market

Due to the COVID-19 outbreak, there has been a significant drop in the number of patient visits to clinics in the first and second quarters of 2020 owing to lockdowns and constraints implemented to prevent the spread of the disease. This has led to a decline in the number of elective eye surgeries being conducted per week in hospitals and clinics during the forecast period. According to the Ophthalmology Times article, elective surgeries have reduced from 200 surgeries to only ten surgeries a week. Additionally, countries like the US have witnessed 15% cancellations in the number of patient visits to examination centers. According to the same article, ophthalmology lost a significant share of patient volume during the coronavirus disease (COVID-19) pandemic. It is estimated that ophthalmic practice volume fell by 81%, led by declination in patients seeking care for glaucoma (88%) and cataract surgery (97%). During this period, government programs helped many practices, like Paycheck Protection Program loans, which helped the ophthalmic industry to restart its operations successfully.

Cornea and Corneal Implant Market Segmental Analysis

The report covers the cornea and corneal implant market by type, transplant type, disease indication, end-user, and region.

Global Cornea and Corneal Implant Market by Type

The various types comprised in the global cornea and corneal implant market are the human cornea and artificial cornea.

The human cornea segment is likely to hold a major market share during the forecast period. The key factors boosting the growth of the market are rising awareness regarding corneal transplantation and eye tissue donations majorly in developing countries.

Global Cornea and Corneal Implant Market by Transplant Type

The various transplant types comprised in the global cornea and corneal implant market are penetrating keratoplasty, endothelial keratoplasty, anterior lamellar keratoplasty, and Keratoprosthesis.

The penetrating keratoplasty segment is likely to hold the majority of the market share during the forecast period. The factors boosting market growth are the rising number of people suffering from eye disorders such as infectious keratitis and injury of the eyeball.

Global Cornea and Corneal Implant Market by Disease Indication

The various disease indications comprised in the global cornea and corneal implant market are fuchs’ dystrophy, fungal keratitis, keratoconus, and others.

The fuchs’ dystrophy segment is likely to hold a major market share during the forecast period. The key factors such as the increasing incidence of the disease and the growing awareness among people regarding early disease diagnosis are driving the market growth.

Global Cornea and Corneal Implant Market by End User

The various end user such as hospitals & ambulatory surgical centers and specialty clinics are comprised in the artificial cornea and corneal implants market.

The hospitals & ambulatory surgical centers segment is likely to dominate the global cornea and corneal implant market during the forecast period. The key factors such as rising incidences of corneal blindness coupled with increasing cases of trauma cases is propelling the growth of the global cornea and corneal implant market.

Geographical Analysis of Global Cornea and Corneal Implant Market

The global cornea and corneal implant market is studied for key countries of the regions such as North America, Europe, Asia Pacific, and the Rest of the World.

North America is likely to hold the majority of the market share of the global cornea and corneal implant market. The market is well established in North America, with the US dominating the market in this region. The large share of North America is mainly attributed to the established healthcare infrastructure combined with higher adoption of sophisticated healthcare technologies, higher budget among end users of ophthalmologic devices, and a large number of manufacturers for corneal implants in the regions.

Market Players of Global Cornea and Corneal Implants Market

The key players in the global cornea and corneal implants market are AJL Ophthalmic, CorneaGen Inc, CorNeat Vision, LinkoCare Life Sciences AB, Presbia plc, Mediphacos, Aurolab, Cornea Biosciences, DIOPTEX GmbH and EyeYon Medical among others.

Key Developments in Global Cornea and Corneal Implants Market
  • June 2020: AJL Ophthalmic received CE Mark approval for ENDO-K PRO. Product approval will enable the company to provide its portfolio to end-users.
  • January 2020: Mediphacos launched Keraring Intrasomal Corneal Ring. The product launch will enable the company to capture market share.

 

Why GIS?

Read More
Single User License

Anatomic Pathology Market
June, 2022

The global anatomic pathology market size was USD 35.6 Bn in 2021 and is anticipated to reach USD 69.6 Bn in 2031, growing at a rate of 6.9% from 2022 to 2031.

Anatomical pathology is the branch of medicine that comprises the study of body organs and tissues. Anatomical pathology is considered one of the diagnostic branches of medicine, coupled with radiology and other pathology specialties (such as microbiology and chemical pathology). Its roles comprise determining the cause of certain diseases and the effect that they are having on the body, assisting with the choice of treatment that will be given, aiding in giving a prognosis, and determining what may have caused a person’s death.

Scope of the Report
Report Attribute Details
Market Size in 2021$35.6 bn
Market Size in 2031$69.6 bn
Growth Rate (2021-31)6.9%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct & Services, Application, End User, and Regions
Key CompaniesF. Hoffmann-La Roche AG, Danaher Corporation, PHC Holdings Corporation, Beckton, Dickson and Company, Abcam plc., Hologic, Inc., Agilent Technologies, Merck KGaA
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Global Anatomic Pathology Market Drivers

Rising incidence of cancer and other target diseases

Cancer is a leading cause of death across the globe, which accounts for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancer are breast, lung, colon and rectum, and prostate cancers. Around one-third of cancer deaths are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Like HPV and hepatitis, cancer-causing infections are responsible for approximately 30% of cancer cases in low and lower-middle-income countries. Many cancers can be cured if detected early and treated effectively.

Global Anatomic Pathology Market Opportunities

The increasing number of clinical trials pertaining to cancer drugs

Anatomic pathology products and services are used in oncology drug trials to analyze quantitative information as well as to detect morphological structures, detect pharmacodynamic markers, and understand drug mechanisms. It is also used to stratify trial subjects based on the responses given by tissues to the drugs. Tissue diagnostics thus facilitate efficient trials and retrospective studies by reducing the cost and time involved in these processes. For instance, in a Phase III study for Roche’s cancer immunotherapy—TECENTRIQ (atezolizumab)—the PD-L1 (programmed death-ligand 1) expression was evaluated using an investigational immunohistochemistry (IHC) test, which was developed by Roche Tissue Diagnostics.

Global Anatomic Pathology Market Restraints

Availability of refurbished products

The availability of refurbished anatomic pathology instruments is a major challenge to the growth of the global anatomic pathology market. LabX (US), AL-TAR (US), Rankin Biomedical Corporation (US), and Swerdlick Medical Systems (US) are some companies offering refurbished anatomic pathology instruments like tissue processors, and staining systems, and microtomes. A number of end-users—mainly small and medium-sized laboratories—look for cost-effectiveness and opt for refurbished systems, particularly in the price-sensitive markets in developing economies. Considering these factors, the demand for refurbished anatomic pathology instruments is likely to increase in the upcoming years, as these systems offer the same functionalities as new equipment at lower costs. This is likely to hamper the revenue of companies offering branded anatomic pathology instruments in the market.

Impact of COVID-19 on Anatomic Pathology Market

Worldwide, the COVID-19 outbreak has impacted every aspect of the diagnostics industry, comprising the anatomic pathology market. In the last few months, the number of patient visits to hospitals has lowered significantly, despite emergency and OPD services being available in hospitals.

Cancer patients have emerged as one of the worst affected patient groups in the COVID-19 pandemic. COVID-19 has had a profound impact on the number of patients undertaking cancer screening, diagnosis, and treatment. The raised pressure owing to the increasing rate of hospitalization of COVID-19 patients had led to the re-profiling of many hospitals and departments, comprising oncology clinics, for treating patients with COVID-19.

Anatomic Pathology Market Segmental Analysis

The report covers the anatomic pathology market by products & services, applications, end-users, and geography.

Anatomic Pathology Market by Products & Services

The various products & services comprised in the global anatomic pathology market are services, consumables, and instruments. The services segment is also sub-segmented into histopathology and cytopathology. The consumables segment is also sub-segmented into antibodies, kits & reagents, probes, and others. Likewise, the instruments segment is also sub-segmented into slide staining systems, tissue processing systems, cell processors, microtomes, embedding systems, cover slippers, and others.

The services segment is likely to hold a major market share during the forecast period. The key factors boosting market growth are the rising geriatric population coupled with increasing incidences of cancer and other chronic diseases.

Anatomic Pathology Market by Application

The various applications comprised in the global anatomic pathology market are disease diagnostics and medical research. The disease diagnostics segment is sub-segmented into cancer and other diseases.

The disease diagnostics segment is likely to hold a major market share during the forecast period. The key factors propelling the market growth are the increasing incidence of cancer and other diseases coupled with growing geriatric populations.

Anatomic Pathology Market by End Users

The end users comprised in the global anatomic pathology market are hospital laboratories, clinical laboratories, and others.

The hospital laboratories are likely to hold a majority of the market share during the forecast period. The market growth of the segment is attributed to the increasing number of patient visits to hospitals, increasing number of in-house diagnostic procedures performed in hospitals, increasing awareness regarding early disease diagnosis, and the availability of reimbursement in the developed market for clinical tests performed in hospitals.

Geographical Analysis of Global Anatomic Pathology Market

The global anatomic pathology market is studied for key countries of the regions such as North America, Europe, Asia Pacific, and the Rest of the World.

North America is likely to hold the majority of the market share of the global anatomic pathology market. The key factors boosting market growth are the increasing prevalence of chronic diseases, rising healthcare expenditure, and the high-quality infrastructure for hospitals and clinical laboratories.

Market Players of Global Anatomic Pathology Market

The key players in the global anatomic pathology market are F. Hoffmann-La Roche AG, Danaher Corporation, PHC Holdings Corporation, Beckton, Dickson and Company, Abcam plc., Hologic, Inc., Agilent Technologies, Merck KGaA, Sakura Finetek, Bio SB, BioGenex, Milestone Medical, Histo-Line Laboratories, Diapath S.p.A, SLEE medical GmbH, Amos Scientific Pty Ltd, MEDITE Medical GmbH, Cell Signaling Technology, Inc., CellPath Ltd., Jinhua Yidi Medical Equipment Co., Ltd., MICROS AUSTRIA, R. K. SCIENTIFIC INSTRUMENT PRIVATE LIMITED, Lupetec, Medimeas, and Bright Instruments among others.

Key Developments in Global Anatomic Pathology Market
  • May 2021: Hologic received FDA approval for ThinPrep Genesis processor. The new instrument streamlines these workflows with advanced automation capabilities comprising a chain of custody verification, which prevents misidentification and allows for more confidence in results.
  • June 2019: PHC Holdings announced the completion of its acquisition of the Anatomical Pathology business of Thermo Fisher Scientific Inc.

 

Why GIS?

Read More
Single User License

Biosurgery Market
June, 2022

The global biosurgery market size was USD 12.4 Bn in 2021 and is anticipated to reach USD 21.2 Bn in 2031, growing at a rate of 5.5% from 2022 to 2031.

Biosurgery is a medical procedure that comprises the use of natural, synthetic, or semi-synthetic materials to seal surgical incisions and wounds. It is majorly used for preventing excessive blood loss, providing adhesion for wound and tissue sealing, and repairing damaged tissue and bones. Biosurgeries are usually conducted through the various hemostatic sealants, soft tissue repair, bone graft substitutes, adhesion prevention, and staple line reinforcement products. They also utilize natural allografts, cultured epithelial autografts, cultured epithelial autografts, and xenografts for minimizing intra and post-operative complications and promoting faster recovery of the patients.

Biosurgery Market Scope and Structure Analysis
Report Attribute Details
Market Size in 2021$12.4 bn
Market Size in 2031$21.2 bn
Growth Rate (2021-31)5.5%
Historic Period2015-2020
Forecast Period2022-2031
Base Year2021
Segments CoveredProduct, Application, End-User, and Region
Key CompaniesJohnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew Plc. (UK), Tissue Regenix Group Plc (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Biom'Up (France), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan)
Regional ScopeNorth America, Europe, Asia Pacific, Central & South America, Middle East & Africa
Analysis CoverageMarket Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments
Market Trends and Drivers

The major factors boosting the growth of the biosurgery market is the increasing volume of surgeries and the growing prevalence of severe trauma injuries. Adhesion formation is a major post-surgical complication, which results in healthcare complications and generally requires repeat surgeries for the treatment of affected patients. Post-surgical adhesion formation leads to different complications in different surgeries, like severe abdominal pain in the case of abdominal surgeries, infertility in women after gynaecological surgeries, and physical impairment of patients after neurological surgeries. Considering the severe effects of post-surgery adhesion formation in patients, the importance of products such as adhesion barriers is increasing in the market. Also, considering the growth in the number of surgeries performed globally, the importance of these products will be more prominent in the forthcoming years.

Likewise, the growing adoption of advanced biosurgery products in emerging markets is also boosting the growth of the biosurgery market. The penetration of biosurgery products is increasing across emerging countries, specifically based in the Asia Pacific, Latin America, and the Middle East and Africa. In the coming years, countries such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the biosurgery market. This is because the markets in these countries are characterized by a large patient base for target indications (like cardiovascular, orthopedic, general/abdominal, and gynecologic disorders), rising health awareness, growing healthcare expenditure, rising medical tourism, coupled with rapidly developing healthcare infrastructure. Over the last few decades, countries such as India and Malaysia have emerged as hubs for medical tourism. This is because the cost of medical procedures across these emerging countries is significantly less in comparison to developed countries such as the US, Germany, France, and the UK. Moreover, government agencies in several Asia Pacific and Middle East countries are undertaking initiatives to support their respective healthcare systems, which is providing lucrative growth opportunities to the biosurgery product manufacturers across emerging countries.

Market Restraints & Challenges

one of the primary challenges in the growth of the global biosurgery market is the high price of biosurgery products and the rising cost of surgical products. The biosurgery market is extremely competitive in terms of pricing, due to the highly competitive intensity among existing players. Most of the products available in this market are priced at a premium. The high cost, combined with the unfavourable reimbursement scenario for these products in emerging countries, makes them unaffordable for a large section of the target patient population. Owing to the high cost of biosurgery products, conventional procedures such as sutures and ligature-based procedures are preferred during surgeries across emerging countries. Adding to that, the biosurgery products currently available in the market are made of complicated reconstitutes with a poor shelf life. So, there is a growing need for low-priced products that are easy to handle and have a better shelf life.

Global Biosurgery Market Segmentation

The report analyses the biosurgery market based on product, application, end-user, and regions.

Global Biosurgery Market by Product

On the basis of product, it is segmented into bone graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. The bone graft substitutes segment is likely to dominate the market during the forecast period. The key factors such as the increasing use of bone-graft substitutes across different types of orthopedic surgeries as they reduced surgical time are propelling the market growth of the segment. The bone substitutes can be broadly categorized into bone grafts (autografts, allografts, xenografts), ceramics and growth factors. The ideal bone substitutes should be biocompatible and not evoke any adverse inflammatory response.

Global Biosurgery Market by Application

Based on application, it is segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, urological surgery, thoracic surgery, and others. The reconstructive surgery segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing number of facial cosmetic surgeries combined with increasing cases of skin injuries, growing incidences of burn injuries, and an increasing number of breast cancer patients undergoing mastectomy and breast reconstruction procedures are the major factors driving the growth of this segment.

Global Biosurgery Market by End User

Based on the end-user, it is segmented into hospitals, clinics, and others. The hospital segment is likely to dominate the market during the forecast period. The key factors attributing to the growth of the market are the increasing number of surgeries taking place across the globe coupled with the rising geriatric population and the incidence of various diseases. Additionally, the increasing need to control blood loss and achieve efficient homeostasis and wound closure in trauma cases, injuries, or surgical procedures is leading to the increasing adoption of biosurgery products by surgeons.

Geographical Analysis of Global Biosurgery Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to dominate the global biosurgery market over the forecast period. This is attributed to the significant number of prominent vendors, a highly developed healthcare system, an increasing number of surgeries, rising obese patients, and an increasing geriatric population. The Asia Pacific region is to grow at the highest CAGR over the forecast period. This can be attributed to the growing aging population, favorable government initiatives, rising per capita income, and increasing investments in the healthcare infrastructure. Europe is expected to hold the second-largest market share over the forecast period.

 

Major Players of the Global Biosurgery Market

The global biosurgery market report includes players such as Johnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew Plc. (UK), Tissue Regenix Group Plc (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Biom’Up (France), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan) among others.

COVID-19 Analysis

According to the International Monetary Fund (IMF), due to the epidemic of a novel coronavirus, the worldwide economy decreased by over 3.0% in 2020. Several nations were under strict lockdowns in 2020 & 2021, which have impacted the supply of raw materials. Therefore, due to this, the manufacturing activities of biosurgery producers have ceased. While some biosurgery is considered urgent, others have been postponed and delayed since the beginning of the global pandemic. The other aspect negatively affecting the market is the drop in the diagnosis of obesity owing to healthcare resources being reserved for COVID-19 patients. Owing to the growing incidence of COVID-19, hospitals became high-risk zones, specifically for patients suffering from chronic conditions. Owing to that, non-critical procedures such as elective surgeries were either canceled or postponed during the first and second quarters of 2020, which resulted in a significant decline in the total number of elective surgical procedures performed. As a result, the demand for biosurgery products witnessed a sharp decline in 2020. The second wave of COVID-19 further deprioritized elective surgical procedures. Governments across the globe have also issued limitations and bans on medical procedures and elective surgeries. With the current pandemic scenario, surgical procedures have witnessed a decline and are only expected to increase in the third quarter of 2021 in countries such as the US. Some countries in the EU have resumed surgical interventions, which has increased the demand for biosurgery products in the region.

Recent Developments
  • November 2021, Triad Life Sciences, has put on the hard hat and is moving forward with plans to raise $40 million in an IPO through Canaccord Genuity.
  • September 2021, Tissue Regenix, the regenerative the medical technology company, announced the launch of DermaPure Meshed and VNWTM, both line extensions to the company’s Biosurgery division, utilizing tissue Regenix’s patented decellularization Technology.
  • April 2021, Aroa Biosurgery Limited, launched a new product named Myriad Morcells, which easily conforms to optimize contact with irregular wound beds.
  • February 2020, Baxter announced 510 (k) clearance from US FDA for Peri-Strips Dry with Veritas Collagen Matrix product with Secure Grip. The product is a staple line reinforcement agent and is indicated for mitigating the bleeding during bariatric surgeries and other surgical procedures.
  • February 2020, Integra Life Sciences Holdings Corp. launched Amnio Excel Plus Placental Allograft Membrane for use across soft tissue repair.
  • October 2020, Orthofix Medical Inc., announced the launch of O-Genesis Graft Delivery System and AlloQuent Structural Allograft Q-Pack, a ready to use cervical and lumbar spacers for allograft procedures.
Biosurgery Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global biosurgery market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of aspects that boost and restrict the development of the market is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future biosurgery market potential from 2021 to 2031 in terms of revenue.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global biosurgery industry.
Frequently Asked Questions

Q. How big is the Biosurgery market?

Ans. The global biosurgery market size was USD 12.4 billion in 2021 and is anticipated to reach USD 21.2 billion in 2031.

Q. What is the Biosurgery market growth rate?

Ans. The growth rate of the Biosurgery market is 5.5% from 2022 to 2031.

Q. Which region holds a major market share for the Biosurgery market?

Ans. North America holds a major market share of the Biosurgery market in 2021.

Q. Which segment accounted for the largest Biosurgery market share?

Ans. By end-user, the hospital’s segment accounted for the largest Biosurgery market share

Q. Who are the key players in the Biosurgery market?

Ans. The global biosurgery market report includes players such as Johnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew Plc. (UK), Tissue Regenix Group Plc (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Biom’Up (France), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan) among others.

Q. What are the factors driving the biosurgery market growth?

Ans. The major factors driving the growth of the market are the increasing volume of surgeries and the growing prevalence of severe trauma injuries.

Q. What are the key growth strategies of biosurgery market players?

Ans. The key growth strategies of biosurgery market players are product launch and product approval.

Q. Which region will provide more business opportunities for the biosurgery market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for biosurgery market during the forecast period

Read More
Single User License